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Overview 
This thesis investigates the effects of the drug ketamine in both clinical and 
recreational populations. Part one presents a literature review investigating the 
effects of long-term ketamine use on cognition. The results indicated that long-term 
ketamine use impairs episodic memory. However, this was not found across all tasks 
reviewed. Evidence looking at working memory and executive functioning provided 
an inconsistent picture. This is in line with previous research where some studies 
have found these domains to be impaired in long-term ketamine users and other 
studies have found no impairments. Methodological issues were considered, 
including the impact of poly-substance use, the presence of mood disorders and the 
lack of consistency in cognitive tasks employed to measure functioning.  
Part two presents an empirical paper exploring the effects of ketamine in 
comparison to lidocaine on mood, subjective drug effects and pain outcomes for 
treating patients with chronic neuropathic pain. Both drugs reduced scores on pain 
measures during the infusion and at a one-week follow-up.  No antidepressant like 
effects were observed in either group. The ketamine group reported feeling more 
intense drug effects, feeling higher and liking the drug more than the lidocaine 
group. However, both drug groups had low ratings for wanting more of the drug, 
suggesting that ketamine is unlikely to be sought outside the pain clinic for its 
reinforcing effects.  
Part three provides a critical appraisal of the research. It describes the process 
of conducting the research, alongside providing reflections on working with patients 
who have chronic pain. This was a joint project with a fellow DClinPsy student, 
Catherine Trotman (Trotman, 2018). Will Lawn (Post-Doc) was also involved in the 
data collection. See Appendix 1. for a breakdown of contributions. 
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Impact Statement 
Chronic neuropathic pain is a significant worldwide health concern. 
Treatment for chronic neuropathic pain is varied, and only 30-40% of patients report 
adequate pain relief in response to first-line treatments. Additionally, depression and 
depressive-like symptoms are often found co-morbidly in people who have chronic 
pain. The presence of depression at baseline has been linked to poorer outcomes in 
chronic pain populations. The current study investigated the effect of the drug 
ketamine, a treatment shown to produce sustained analgesia in this population, and 
rapid-acting antidepressant effects in treatment-resistant depressed populations. 
Patients being treated with ketamine were compared with those being treated with 
the drug lidocaine.  Measures used were indices of pain, mood, and subjective 
reinforcing effects of the drug.  
Both ketamine and lidocaine participants showed significant pain relief at the 
one-week follow-up when compared to scores at baseline. Further, the study found 
that patients being treated with ketamine felt significantly more intense drug effects, 
feeling higher and liking the effects of the drug more than those who were treated 
with lidocaine.  However, ketamine patients’ ratings showed they did not want more 
of the drug. Further, ketamine does not have a significant anti-depressant effect on 
patients with chronic pain.  
The current study adds to the evidence base for the use of ketamine in 
treating chronic neuropathic pain in that significant reductions in pain measures were 
achieved. Currently, there are no standardized protocols in clinical practice for what 
dose of ketamine or treatment frequency should be used in treating chronic pain. 
These results will add to the growing literature which will inform this process.   
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The study also indicated that the chronic pain population may show a 
different response to healthy volunteers regarding the subjective drug effects. The 
ketamine group reported greater acute reinforcing drug effects than the lidocaine 
group (feeling high, liking the drug), but ketamine participants did not want more of 
the drug. This is a significant finding, as it may indicate a low abuse potential in the 
chronic pain population. This is significant when considering the use of ketamine as 
a treatment in clinical practice and will add to the literature that will inform the use 
of ketamine in future treatments.  
Ketamine did not show any specific anti-depressant effects in our 
participants. Therefore further research is needed to investigate ketamine's anti-
depressant properties across different patient groups. 
These results will be disseminated locally to the pain clinic as well as through 
publication to inform academics and clinical practitioners.  
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Abstract  
Aim: The recreational use of ketamine has been increasing over the past 
decade. Literature shows that ketamine, in acute doses, robustly impairs a number of 
cognitive functions. However, literature examining the effects of chronic ketamine 
use has been less conclusive. This review provides a narrative synthesis of evidence 
examining the effects of chronic ketamine use on cognition. 
Method: A systematic review of case-control studies investigating the effects 
of chronic ketamine use on cognition in humans was performed through electronic 
database searches. Articles were selected from peer-reviewed journals published 
between January 2008 and April 2018. The Newcastle-Ottawa Scale was used to 
assess the methodological quality of the studies included.  
Results: 11 studies met the inclusion criteria for the current review. All 
studies scored either high (6) or medium (5) on the quality assessment. Nine studies 
employed drug naïve control groups, six studies employed other drug using groups 
and four studies employed ex-ketamine using controls. Results were considered 
across four cognitive domains: Declarative Memory, Working Memory, Executive 
Functions and Component Processes. The evidence suggests that chronic ketamine 
use most robustly impairs episodic memory functions. Impairments were 
inconsistently reported across studies in the domains of working memory, executive 
functions and component processes.  
Conclusion: This review provides preliminary support for the existence of 
impairments in episodic memory function in chronic ketamine users.  Findings in 
other cognitive domains are inconclusive. This review highlights the need for 
replication studies and the methodological issues that need to be considered when 
using naturalistic populations of drug users. Future research should examine the 
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impact of drug use patterns (frequency, average amount used per session, lifetime 
usage, poly-drug use) on cognitive functioning. 
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Introduction 
Ketamine is a non-competitive N-Methyl-D-Aspartate Receptor (NMDA-R) 
antagonist which affects the action of the amino acid class of neurotransmitters. 
Ketamine was originally designed as a less powerful analogue of the anaesthetic drug 
phencyclidine (PCP) which was known to induce psychotomimetic symptoms. 
Ketamine has been used in anaesthesia for over 50 years and has a well-established 
safety profile, especially because it does not repress the respiratory system.  Thus, 
ketamine can be used in situations where sophisticated resuscitation equipment is not 
available, including field/war scenarios.  Indeed, ketamine is on the World Health 
Organisation’s list of essential medicines. Furthermore, ketamine, at sub-anaesthetic 
doses, has also been shown to produce good analgesia in patients experiencing 
neuropathic pain (Lynch et al., 2005), a condition that is particularly hard to treat 
effectively with other agents.  In addition to this, recent evidence has shown 
intravenous and intranasal ketamine administration to produce rapid antidepressant 
effects in populations of depressed patients that have not responded to other 
treatments for depression (Krystal 2007; Salvadore and Singh, 2013; Young, 2013).  
 
Emergence Phenomena 
Patients being treated with ketamine have often reported experiencing a range 
of psychedelic symptoms while recovering from ketamine anaesthesia. These 
reported symptoms have been labelled ‘emergence phenomena’ and include, 
hallucinations, delusions, confusion, out-of-body experiences and ‘near-death’ 
experiences. These have limited the use of ketamine in adult humans.  However, 
these same effects have contributed to the use of acute ketamine as a 
pharmacological way of modelling psychosis in human and animal studies. Both 
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anecdotal reports and evidence from controlled studies have demonstrated that in 
acute doses ketamine induces reliable, yet reversible, dose-related positive and 
negative schizophrenia-like symptoms (e.g. Jansen, 1990; Krystal et al., 1994; 
Morgan, Rossell et al., 2006). In addition to this, research indicates that ketamine 
mimics the symptoms of schizophrenia more closely than any other drug (Newcomer 
& Krystal, 2001). 
 
Acute Effects of Ketamine on Memory and Cognition 
Indeed, in acute doses, ketamine has the potential to significantly impact 
cognitive and psychological functioning via the dense population of NMDA-R 
located within the cerebral cortex and hippocampus (Aalto et al., 2002; Breier et al., 
1997). Furthermore, The NMDA-R is thought to be important in long-term 
potentiation, a form of synaptic plasticity which is central to learning and memory 
(Harris et al., 1984). Thus, given that ketamine’s principal action is at the NMDA-R, 
the effects of acute ketamine use on cognition have been of interest to researchers.  
Acutely, ketamine produces transitory, dose-dependent memory impairment in 
healthy volunteers. These transitory impairments have been found in the domains of 
working memory (Krystal et al. 2005, Morgan et al. 2004a) and declarative memory 
(Morgan et al. 2004a, 2004b, Parwani et al. 2005, Rowland et al. 2005). However, 
research investigating ketamine’s acute effects on executive functioning has 
produced an inconsistent picture. For instance, performance was found to be intact 
on the Stroop Task (Parwani et al. 2005) and Trail Making Task (Morgan et al. 
2004a) but impaired on the Hayling Test (Morgan et al. 2004b) and Wisconsin Card 
Sorting Test (Krystal et al. 1999, 2000).  
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Recreational Use  
Ketamine is also used widely as a recreational drug, in part because of the 
psychotomimetic effects described above. Recreational use has become more 
mainstream over the past decade, with the drug moving from being used 
predominantly as a ‘club drug’, in specific sub-cultures, to its broader use as a party 
drug across many populations. Ketamine’s recreational use has been reported in 59 
countries including Australia, UK, USA and Hong Kong (United Nations Office on 
Drug Control, 2016). Recent lifetime prevalence statistics are 2.6% in 16-24-year-
olds in the UK, 1.5 % in 12th-grade students in the USA and 1.7% in 14 years and 
older youth in Australia (United Nations Office on Drug Control, 2016). Further to 
this, ketamine users are more likely than those who use other illicit drugs to report 
poly-substance use. Hoare (2010) reported that only 3% of ketamine users surveyed 
in their study reported only using ketamine, and not any other illicit substances, over 
the past year. 
 
Abuse 
Ketamine abuse is reported as a worldwide public health concern (Liao et al., 
2017). Indeed, ketamine was reportedly the second most commonly abused drug in 
Hong Kong in 2014 (Narcotics Division, Security Bureau, 2015). Long-term 
ketamine use can lead to serious side effects, including bladder and renal 
complications, such as ketamine-induced ulcerative cystitis and stomach ulcers. 
These can lead to severe complications with long-term consequences (Morgan & 
Curran, 2012). The evidence is not clear with regards to whether ketamine results in 
physical dependence (Critchlow 2006; Ricaurte & McCann, 2005). However, 
research shows that the psychological properties that ketamine posses, especially the 
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high which is experienced, lead to its abuse potential (Krystal et al., 1999). Further to 
this, due to ketamine’s short half-life (180 mins) (Celmens et al., 1982), it tends to 
result in only mild ‘hangovers' which may increase the likelihood of its abuse. 
Evidence also suggests that long-term ketamine use impacts cognitive functioning 
(Morgan & Curran, 2012). 
 
Methodological Considerations in Chronic Ketamine Use Research  
Given ketamine is a drug that is only given in controlled doses, in medical 
environments, and has been shown to have significant physiological and cognitive 
impacts, it is not ethical to conduct controlled studies on the effects of repeated 
dosing in study populations. Thus, to study the effects of chronic ketamine use, 
naturalistic populations (i.e. populations who self-administer recreationally) are the 
only way to investigate the effects of chronic ketamine use on humans. Further, as 
discussed above those who use drugs recreationally generally use other substances as 
well. Thus, isolating the effects of ‘pure' ketamine use can be challenging to achieve. 
 
Chronic Ketamine Use and its Effects on Cognition 
The majority of studies to date have utilised recreational ketamine users to 
examine the cognitive effects of chronic ketamine use. However, reports on how 
long-term ketamine use effects cognition have been sparse and inconsistent. For 
instance, in a recent review (Morgan and Curran, 2012) only three publications on 
cognitive impairment in long-term ketamine use were identified. Morgan and 
Curran’s (2006) review, of the acute and chronic effects of ketamine use on memory, 
reported that chronic ketamine use had specific yet wide-ranging effects on memory 
systems. In general, the findings seem to corroborate those found in research looking 
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into the acute effects of ketamine on healthy volunteers. Episodic memory was found 
to be impaired in ketamine users across a range of paradigms. Further to this, long-
term ketamine use may cause a greater degree of impairment, in this domain, than 
those that have been reported after acute doses of ketamine in healthy volunteers. 
However, measures of working memory, attention and executive functioning have 
shown less consistent results. Overall, previous research indicates that acute 
ketamine use impairs working memory (Curran & Monaghan, 2001; Curran and 
Morgan, 2000; Morgan, Monaghan et al., 2004) but longer-term effects are 
inconclusive. Findings for executive functioning and attention paradigms have also 
yielded mixed results with some studies finding impairment (Curran and Morgan, 
2000; Morgan et al., 2009) but some studies finding these domains to be intact 
(Morgan et al., 2004b). Thus, given that ketamine is now used widely as a ‘club 
drug’, and frequent use is rising across the world, it is important to review the most 
recent evidence examining the effects of chronic ketamine use. 
 
Objective of the Current Review 
To the best of the author’s knowledge, there has been no systematic review of 
the literature examining the effects of chronic ketamine use in the last 10-years. The 
current review, therefore, aims to update the chronic use sections of Morgan and 
Curran’s (2006 and 2012) papers and expand on these by examining recent research 
into the impact of chronic ketamine use on cognition. This will be addressed with a 
review of studies from the past ten years (2008-18).  
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Methods 
Search Strategy  
A systematic literature search was carried out using three electronic databases 
(PsycINFO), EMBASE and MEDLINE). Search terms related to ketamine were 
combined with terms associated with cognitive functioning and chronic drug use (see 
table 1 for details). The focus of this review was specific to 
neuropsychological/cognitive studies. However, the initial search strategy was 
designed to be as exhaustive as possible. Once duplicate citations were removed 983 
citations remained. The abstracts of these articles were then assessed with the 
following criteria in mind: 
1) The target population included adults (over 18) who reported long-term-frequent 
ketamine use 
2) The study reported results from tests of cognitive functioning 
3) The study was published in a peer reviewed journal 
4) The study was reported in English 
5) The study was published between January 2008 and April 2018 
6) The study did not use case studies 
7) A comparison (control) group was used 
 
Studies that appeared to meet these criteria were then subject to a more 
detailed evaluation. 11 articles were found to meet the inclusion criteria. One paper 
was excluded on the basis that its focus was on a highly specific aspect of learning 
(associative blocking to reward-predicting cues), thus would not have been 
comparable with the others studies included in this review which focused of broader 
aspects of cognitive functioning. This search is summarised in Figure 1. 
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Data Extraction 
For each study, the sole reviewer extracted age, gender, ketamine use data, 
cognitive domains investigated, experimental tasks employed and key cognitive 
findings.  The primary results of interest were group differences in performance on 
cognitive tasks and group differences in the extent of ketamine use. 
 
Table 1: Summary of Systematic Review Search Terms 
Key concepts Ketamine Cognitive effect Chronic use 
Alternative terms “ketamine”  
“ketalar” 
“NMDA receptor 
antagonist” 
“ketanest”  
“keta*” 
“esketamine” 
 
“cognition” 
“cognitive dysfunction” 
“cognitive impairment” 
“executive function” 
“information processing” 
processing speed”  
“reaction time”  
“learning”  
“memory”  
“dissociat*” 
“k-hole”  
“positive symptom*” 
“negative symptom” 
“priming” 
“decision making”  
“judgement” 
“substance*” 
“drug*” 
“misuse” “ 
dependen*”  
“abuse” 
“chronic” 
“addict*” 
“addiction”  
 
 
 
Figure 1: Literature Search Results, Figures and Selection Strategy 
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Quality and Relevance Assessment 
A quality and relevance assessment of the studies was carried out.  All studies 
included in this review employed a cross-sectional design. Thus, the Newcastle-
Ottawa Scale (NOS), (Wells et al., 2004), a tool to aid researchers conducting 
systematic reviews and meta-analyses, in assessing the quality of non-randomised 
studies, was utilised. The NOS utilises a star rating system to evaluate the studies 
across three broad categories: the selection procedure for study groups; how 
comparable the groups are; the ascertainment of either the exposure or outcome of 
interest for case-control or cohort studies respectively. An overall rating system of 
quality for the current review was developed based on the NOS star ratings. Studies 
scoring seven or more stars were rated as high in both relevance and quality, studies 
scoring five to six stars were rated as medium in quality and studies scoring less than 
four stars were rated as low. 
Six studies fell into the high category and five studies in the medium category 
as depicted in table 2 below. 
 
Table 2: Summary of Quality and Relevance Assessment 
Study Year Selection Control  Outcome Overall 
Rating 
Chan et al.,  2013 ** * ** Medium 
Cheng et al., 2018 ** ** *** High 
Liang et al.,  2013 *** * ** Medium 
Minseung Kim et al.,  2016 * * *** Medium 
Morgan et al. 2009 **** ** *** High 
Morgan et al.,  2010 **** ** *** High 
Morgan, Duffin et 
al.,  
2012 *** ** *** High 
Stefanovic et al. 2009 **** ** *** High 
Tang et. al., 2013 *** * ** Medium 
Zeng et al., 2016 ** * *** Medium 
Zhang et al.,  2018 **** ** *** High 
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Results 
A summary of studies entered into the review is provided in table 3. Table 4 
provides a summary of ketamine use across the studies. 
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Table 3 Summary of Results and Study Characteristics 
Study, 
Year and 
reference 
Country Type of 
Study 
Sample Size and 
Characteristics 
Other 
Controls/Measures 
reported 
Cognitive Test  Cognitive Domain Main results  
Chan, et al 
2013 
China  Case-
Control 
55 Participants. 
Ketamine Users: 
n=25, M:F=11:14. 
Mean age = 
19.84±3.53. 
Control: n=30, 
M:F=11,19. Mean age 
= 18.90±2.86. 
To control for poly-
drug use, the study 
included ketamine 
users who have no 
more than monthly 
use of cannabis 
and/or weekly use 
of cocaine, ecstasy, 
and 
methamphetamine. 
 
 
Stroop Test. 
Verbal Fluency Test. 
Ruff Figural Fluency 
Test. 
Symbol Digit Modalities 
Test. 
Digit Vigilance Test. 
Chinese Auditory-
Verbal Learning Test. 
Continuous Visual 
Memory Test. 
 
Executive Function. 
Psychomotor 
Function. 
Attention. 
Declarative 
Memory. 
Impairments in verbal fluency, 
cognitive processing speed and 
verbal learning were observed in 
the frequent ketamine user group.  
Furthermore, correlation analysis 
showed a negative association 
between between longer life time 
usage and verbal learning 
performance. 
Cheng et 
al., 2018 
China Case- 
Control 
130 Participants. 
Ketamine users 
(KNP): n=51, 
M:F=36:15. Mean age 
= 30.00±6.20. 
Ketamine Users with 
Persistent Psychotic 
Symptoms (KPP) 
n=23, M:F=18:5. 
Mean age = 
30.30±7.10. 
Schizophrenic 
Patients (SZ): n=75, 
M:F=38:37. Mean age 
= 39.50 ± 8.10. 
 
Urine Testing to 
confirm group 
membership. 
Groton Maze Learning 
Task. 
Social Emotional 
Cognition Task. 
One Back Task. 
Detection Task. 
Identification Task. 
International shopping 
List Task and Delayed 
Recall Task. 
 
 
Social Cognition. 
Working Memory. 
Attention/Vigilance. 
Declarative 
Memory. 
Chronic heavy ketamine abusers 
with persistent psychotic 
symptoms beyond ketamine 
discontinuation (KPP) showed a 
higher degree of impairment in 
verbal memory and spatial 
problem solving than the group of 
ketamine users who displayed no 
psychotic symptoms (KNP). 
Secondly, the study reported that 
participants with diagnoses of 
schizophrenia (SZ) showed 
significantly more cognitive 
impairment than the KNP group. 
However, the KPP group showed a 
similar cognitive profile to the SZ 
group.  
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Liang et 
al., 2013 
China Case-
Control 
196 Participants. 
Current Users: n=32, 
M:F=19:13. Mean age 
= 20.7±4.1. 
Former Users: n=64, 
M:F=36:28. Mean age 
= 20.1±3.6. 
Control: n=100, 
M:F=58:42. Mean age 
= 20.6±3.6. 
 
Univariate General 
Linear Model 
(GLM) was used to 
control for the 
potentially 
confounding 
factors including 
age, sex, years of 
education and BDI3 
score as covariates. 
Stroop Test. 
Modified Verbal  
Fluency Test. 
Wisconsin Card Sorting 
Test. 
Digit Span Backwards. 
Short Form of the 
Wechsler Adult 
Intelligence Test. 
WMS4: Logical 
Memory.  
WMS: Word List. 
Rey–Osterrieth Complex 
Figure. 
Executive Function. 
Working Memory. 
General IQ. 
Declarative 
Memory. 
Verbal and visual memory 
impairments were found in the 
ketamine with poly-drug use group 
and the ex-ketamine user group. 
 
Minseung 
Kim et al., 
2016 
Korea Case-
Control 
30 Participants. 
Long-term Frequent 
Ketamine 
Treatment: n=14, 
M:F=12:2. Mean age 
= 38.57±8.36. 
Non-Long-term 
Frequent Ketamine 
Treatment: n=16, 
M:F=8:8. Mean age = 
37.50±9.30. 
 
None Stated Stroop Colour Test. 
Trail Making Test. 
Digit Symbol. 
Digit Span. 
Controlled Oral Word 
Association Test 
(COWAT). 
Executive Function. 
Psychomotor 
Function. 
Working Memory. 
Declarative 
Memory. 
Impairments in working memory, 
processing speed and tests of 
executive functioning were found 
in the long-term frequent ketamine 
infusion group. These impairments 
were not observed in the control 
group. 
 
 
Morgan et  
al.,2009 
U.K. Case-
Control 
150 Participants. 
Frequent Ketamine: 
n=30, M:F=19:11. 
Mean age = 
25.87±9.23. 
Infrequent 
Ketamine: n=30, 
(M:F=24:6). Mean 
age =27.37 ±6.73 
Hair samples 
analysed for drug 
use confirmation. 
Pre-morbid IQ. 
Years in Education. 
Family History of 
mental illness. 
Fluency. Semantic and 
phonological tasks 
Stockings of Cambridge 
(SOC). 
Spot the word. 
CANTAB1: Spatial 
working memory. 
CANTAB: Pattern 
recognition memory. 
Executive Function. 
Pre-morbid IQ. 
Working Memory. 
Declarative 
Memory. 
 
 
 
Impairments in working memory, 
episodic memory, aspects of 
executive functional and reduced 
psychological wellbeing were 
found in long-term frequent 
ketamine users. No impairments 
were found in recreational 
ketamine users. 
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Ex-Ketamine: n=30, 
M:F=20:10. Mean age 
= 27.3±5.31. 
Poly-drug control: 
n=30, M:F=22:10. 
Mean age = 
29.63±9.27. 
Non-Drug Control: 
n=30, M:F=21:9. 
Mean age = 
24.8±5.83. 
 
Source memory task. 
Prose recall subtest of 
RBMT2. 
Hayling. 
Morgan et 
al., 2012 
U.K. Case-
Control 
130 Participants. 
Ketamine users: 
n=21, M:F=12:9. 
Mean age = 
25.05±7.61. 
Cannabis users: 
n=29, M:F=20:9. 
Mean age = 
20.86±3.71. 
Cocaine users: n=22, 
M:F=15:7. Mean age 
= 35.32±7.33. 
Recreational Poly 
Drug users: n=28, 
M:F=10:18. Mean age 
= 28.07±7.38. 
Drug Naïve 
Controls: n=30, 
M:F=18:12. Mean age 
= 29.83±11.49. 
 
None reported. Spot the Word. 
Digit Span. 
Prose Recall RBMT. 
 
 
 
Pre-morbid IQ. 
Working Memory. 
Declarative 
Memory. 
 
 
 
 
 
 
 
 
Ketamine and cannabis groups 
showed the greatest impairment on 
attentional aspects of tasks. The 
authors highlight that the cognitive 
profile of dependent ketamine 
users is similar to that of 
prodromal individuals who 
transitioned to psychosis. 
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Morgan et 
al.,2010 
U.K. Longitudinal 120 Participants. 
Frequent Ketamine: 
n=25, M:F=15:10. 
Mean age = 
25.87±9.23. 
Infrequent 
Ketamine: n=26, 
M:F=21:5. Mean age 
=27.5 ±6.98. 
Ex-Ketamine: n=23, 
M:F=15:8. Mean age 
= 27.26±3.84. 
Poly-drug Control: 
n=25, M:F=17:7. 
Mean age = 
31.29±9.47. 
Non-Drug Control: 
n=21, M:F=14:7. 
Mean age = 
25.05±6.67. 
 
Hair samples 
analysed for drug 
use confirmation. 
Pre-morbid IQ. 
Years in Education. 
Family History of 
mental illness. 
Fluency. Semantic and 
phonological tasks 
Stockings of Cambridge 
(SOC). 
Spot the word 
CANTAB: Spatial 
working memory. 
CANTAB: Pattern 
recognition memory. 
Source memory task. 
Prose recall subtest of 
RBMT. 
Hayling. 
Executive Function. 
Pre-morbid IQ. 
Working Memory. 
Declarative 
Memory. 
 
 
 
At the 12-month follow-up results 
showed that the cognitive deficits 
observed in long-term frequent 
ketamine users were still present. 
A correlation was found where an 
increase in ketamine use was 
negatively associated with 
performance on spatial working 
memory and pattern recognition 
tasks. 
 
Stefanovic, 
et al, 2009 
UK  Case- 
Control 
96 Participants. 
Ketamine users: 
n=22, M:F=19:3. 
Mean age = 
21.00±2.24. 
Recreational Poly 
Drug users: n=26, 
M:F=18:8. Mean age 
= 21.00±1.03. 
Drug Naïve 
Controls: n=48, 
M:F=26:22. Mean age 
= 20.15±2.01. 
 
Urine Testing to 
confirm group 
membership. 
Semantic Priming 
Paradigm. 
Semantic Memory. No differences in semantic priming 
were found between the ketamine 
user group and the non-drug using 
control group. 
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Tang et al., 
2013 
China Case 
Control 
200 Participants. 
Current Users: n=51, 
M:F=29:22. Mean age 
= 22.80±4.3. 
Former Users: n=49, 
M:F=24:25. Mean age 
= 22.0±4.0. 
Control: n=100, 
M:F=58:42. Mean age 
= 20.6±3.6. 
 
Cognitive functions 
were adjusted for 
age, gender, and 
education using 
ANCOVA6. 
Stroop Test. 
Modified Verbal 
Fluency Test . 
Digit Symbol Coding. 
Digit Span. 
Arithmetic WAIS III7. 
Logical Memory. 
Rey-Osterrieth Complex 
Figure. 
Executive Function. 
Psychomotor 
Function. 
Working Memory. 
Declarative 
Memory. 
Frequent ketamine users showed 
impaired in mental and motor 
speed, visual and verbal memory, 
and executive functions. Frequent 
ketamine users also displayed a 
higher number of depressive 
symptoms. Significant correlations 
between depressive scores and 
working memory were found. 
Zeng et al., 
2016 
China Case-
Control 
170 Participants. 
Ketamine Users: 
n=51, M:F=29:22. 
Mean age = 
25.72±5.83. 
Methadone Users: 
n=60, M:F=36:23. 
Mean age = 
42.48±5.09. 
Control: n=60, 
M:F=30:30. Mean age 
= 23.25±3.47. 
 
Urine Testing to 
confirm group 
membership. 
Stroop Test. 
Stop Signal. 
Iowa Gambling Task. 
Raven's Progressive 
Matrices. 
2-Back. 
Barratt's Impulsivity 
Scale. 
Executive Function. 
Decision Making. 
General IQ. 
Working Memory. 
Impulsivity. 
 
Ketamine and methadone users 
showed significantly higher levels 
of self=reported impulsivity and 
antisocial traits than the non drug 
using control group. The ketamine 
group showed significantly poorer 
performance on working memory 
tasks than either the methadone or 
control groups.  Both ketamine and 
methadone users showed 
impairments on the response 
inhibition task.  
 
Zhang et 
al., 2018 
China  Case-
Control 
200 Participants. 
Ketamine (non 
heavy other drug) 
users8: n=286, 
M:F=186:100. Mean 
age = 25.3±4.8. 
Ketamine (heavy 
other drug) users9: 
n=279, M:F188:91. 
Mean age = 24.0±5.0. 
Cognitive task 
scores were 
analysed with a 
univariate general 
linear model with 
age, sex, education 
and BDI scores as 
covariates. 
Stroop Test. 
Wisconsin Card Sorting 
Test. 
Digit Span. 
Logical Memory. 
Rey-Osterrieth Complex 
Figure. 
Executive Function. 
Working Memory. 
Declarative 
Memory. 
Both the non-heavy other drug user 
and heavy other drug user 
ketamine groups showed 
impairments tasks of verbal and 
visual memory. Both groups 
showed no impairment on task of 
working memory and executive 
functioning. Furthermore, no 
significant differences, in terms of 
task performance, were found 
between the two ketamine user 
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Control: n=261, 
M:F=128:133. Mean 
age = 22.9±5.1. 
 
groups. However, a higher average 
amount of ketamine used per 
session was negatively associated 
with performance in the short-term 
verbal memory for the heaving 
other drug using ketamine group. 
 
1 CANTAB: Cambridge Neuropsychological Test Automated Battery, 2 RBMT: Rivermead behavioural memory test, 3 BDI: Beck Depression Inventory, 4 WMS: Wechsler Memory Scale, 5 
CRPS: Complex Regional Pain Syndrome, 6 ANCOVA: Analysis of covariance, 7 WAIS III: Wechsler Adult Intelligence Scale, 8 Ketamine (non heavy other drug) users:  Used ketamine and a 
low frequency of other drugs, 9  Ketamine (heavy other drug) users: Used ketamine and a high frequency of other drug i.e. used other recreational drugs more than 24 times over 6 months within 
the past 2 years in addition to ketamine, 10  PANSS: Positive and Negative Syndrome Scale. 
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Table 4 Summary of Ketamine Use Across Studies Selected for Review	
Study, 
Year and 
reference 
Country Type of 
Study 
Sample Size and 
Characteristics 
Ketamine use  Length of Ketamine 
Use 
Current Amount 
per Session (Grams) 
Days since last use 
Chan, et al 
2013 
China  Case-
Control 
55 Participants. 
Ketamine Users: n=25, 
M:F=11:14. Mean age = 
19.84±3.53. 
Control: n=30, 
M:F=11,19. Mean age = 
18.90±2.86. 
Reported 
Frequency:  
Ketamine Users: Not 
stated but users were 
recruited on basis 
that they reported 
using ketamine at 
least once a month 
for the past 2 years. 
 
Reported Time: 
Ketamine users had 
been using > 2 years. 
Not Reported. All participants that entered 
the study were required to 
abstain from all drugs and 
alcohol for 48 hours. 
Cheng et 
al., 2018 
China Case- 
Control 
130 Participants. 
Ketamine users (KNP): 
n=51, M:F=36:15. Mean 
age = 30.00±6.20. 
Ketamine Users with 
Persistent Psychotic 
Symptoms (KPP) n=23, 
M:F=18:5. Mean age = 
30.30±7.10. 
Schizophrenic Patients 
(SZ): n=75, M:F=38:37. 
Mean age = 39.50 ± 8.10. 
 
Reported 
Frequency: Days 
Per Month 
Ketamine users: 
26.9 ± 8.2. 
Ketamine Users 
with PPS: 24.6 ± 
10.3. 
Reported Time: 
Years. Ketamine 
users: 7.5 ± 4.3. 
Ketamine Users 
with PPS: 6.0 ± 3.8. 
Ketamine users: 4.3 
± 2.7. 
Ketamine Users 
with PPS: 2.4 ± 2.1. 
Participants were required 
to have been abstinent for 
at least 10 days prior to 
study participation.  
Liang et 
al., 2013 
China Case-
Control 
196 Participants. 
Current Users: n=32, 
M:F=19:13. Mean age = 
20.7±4.1. 
Former Users: n=64, 
M:F=36:28. Mean age = 
20.1±3.6. 
Reported 
Frequency: Days 
Per Month. 
Current Users: 4.1 
± 8.9. 
Reported Time: 
Months. 
Current Users: 43.1 
± 48.0. 
Not reported. Current Users: 10.3 ± 
10.9. 
Former Users: 213.2 ± 
151.4 . 
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Control: n=100, 
M:F=58:42. Mean age = 
20.6±3.6. 
 
Minseung 
Kim et al., 
2016 
Korea Case-
Control 
30 Participants. 
Long-term Frequent 
Ketamine Treatment: 
n=14, M:F=12:2. Mean age 
= 38.57±8.36. 
Non-Long-term Frequent 
Ketamine Treatment: 
n=16, M:F=8:8. Mean age 
= 37.50±9.30. 
 
 
Reported 
Frequency: Days of 
use over a 6-month 
period 
Long-term 
Frequent Ketamine 
Treatment: 41.7 ± 
13.7. 
Non-Long-term 
Frequent Ketamine 
Treatment: 2.9 ± 
3.3. 
Reported Time: 
Years. 
Long-term Frequent 
Ketamine 
Treatment:3.82 ± 
1.3. 
Non-Long-term 
Frequent Ketamine 
Treatment: 1.86  ±  
2.2. 
Not Reported. Not reported. 
Morgan et  
al.,2009 
U.K. Case-
Control 
150 Participants. 
Frequent Ketamine: 
n=30, M:F=19:11. Mean 
age = 25.87±9.23. 
Infrequent Ketamine: 
n=30, (M:F=24:6). Mean 
age =27.37 ±6.73. 
Ex-Ketamine: n=30, 
M:F=20:10. Mean age = 
27.3±5.31. 
Poly-drug control: n=30, 
M:F=22:10. Mean age = 
29.63±9.27. 
Non-Drug Control: n=30, 
M:F=21:9. Mean age = 
24.8±5.83. 
Reported 
Frequency: Days 
Per Month. 
Frequent Ketamine: 
20.13 ± 2.36. 
Infrequent 
Ketamine: 3.25 ± 
2.55. 
Reported Time: 
Years 
Frequent Ketamine: 
6.07 ± 4.89. 
Infrequent 
Ketamine: 4.20 ± 
2.20 . 
Ex-Ketamine: 7.63  
±  2.63. 
Frequent Ketamine: 
3.80 ±  2.36. 
Infrequent 
Ketamine: 1.28  ±  
1.13. 
Frequent Ketamine: 1.6 ± 
1.27. 
Infrequent Ketamine: 
11.3 ± 9.36. 
Ex-Ketamine: 344.43  ±  
624.72. 
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Morgan et 
al., 2012 
U.K. Case-
Control 
130 Participants. 
Ketamine users: n=21, 
M:F=12:9. Mean age = 
25.05±7.61. 
Cannabis users: n=29, 
M:F=20:9. Mean age = 
20.86±3.71. 
Cocaine users: n=22, 
M:F=15:7. Mean age = 
35.32±7.33. 
Recreational Poly Drug 
users: n=28, M:F=10:18. 
Mean age = 28.07±7.38. 
Drug Naïve Controls: 
n=30, M:F=18:12. Mean 
age = 29.83±11.49. 
 
Reported 
Frequency: Days 
Per Month 
Ketamine users: 
30.00 ± 0. 
Cannabis users: 
0.17 (0.76). 
Cocaine users: 0.00 
(0.00). 
Recreational Poly 
Drug users: 4.93 
(5.78) 
 
Reported Time: 
Years. Ketamine 
users: 5.65 ± 3.48. 
Cannabis users: 0.02 
± 0.09. 
Cocaine users: 0.19 
± 0.85. 
Recreational Poly 
Drug users: 4.30 ± 
3.54. 
 
Ketamine users: 
3.32 ± 2.13. 
Cannabis users: 0.02 
± 0.06. 
Cocaine users: 0.00±  
0.00. 
Recreational Poly 
Drug users: 1.13 ± 
1.46. 
 
Not Reported. 
Morgan et 
al.,2010 
U.K. Longitudinal 120 Participants. 
Frequent Ketamine: 
n=25, M:F=15:10. Mean 
age = 25.87±9.23. 
Infrequent Ketamine: 
n=26, M:F=21:5. Mean age 
=27.5 ±6.98. 
Ex-Ketamine: n=23, 
M:F=15:8. Mean age = 
27.26±3.84. 
Poly-drug Control: n=25, 
M:F=17:7. Mean age = 
31.29±9.47. 
Non-Drug Control: n=21, 
M:F=14:7. Mean age = 
25.05±6.67. 
 
Reported 
Frequency: Days 
Per Month. 
Frequent Ketamine: 
16.0 ± 10.01.  
Infrequent 
Ketamine: 4.70 ± 
6.48.  
Reported Time: 
Years. 
Frequent Ketamine: 
6.07 ±  4.89. 
Infrequent 
Ketamine: 4.20 ±  
2.20 3.69. 
Ex-Ketamine: 7.63  
±  2.63. 
Frequent Ketamine: 
2.18 ± 1.82. 
Infrequent 
Ketamine: 1.11  ±  
1.06. 
Frequent Ketamine: 
35.44 ± 94.59.  
Infrequent Ketamine: 
26.46 ± 61.82.  
Ex-Ketamine: 34.71  ±  
50.49.  
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Stefanovic, 
et al, 2009 
UK  Case- 
Control 
96 Participants. 
Ketamine users: n=22, 
M:F=19:3. Mean age = 
21.00±2.24. 
Recreational Poly Drug 
users: n=26, M:F=18:8. 
Mean age = 21.00±1.03. 
Drug Naïve Controls: 
n=48, M:F=26:22. Mean 
age = 20.15±2.01. 
 
Reported 
Frequency: Days 
Per Month 
Ketamine users: 
17.79 ± 11.05. 
 
Reported Time: 
Years Ketamine 
users: 3.30 ± 2.92. 
Ketamine users: 
0.99 ± 0.85. 
 
Ketamine users: 3.74 ± 
5.10. 
Tang et al., 
2013 
China Case 
Control 
200 Participants. 
Current Users: n=51, 
M:F=29:22. Mean age = 
22.80±4.3. 
Former Users: n=49, 
M:F=24:25. Mean age = 
22.0±4.0. 
Control: n=100, 
M:F=58:42. Mean age = 
20.6±3.6. 
 
Reported 
Frequency: Days 
Per Month 
Current Users: 17.4 
± 10.9. 
 
Reported Time: 
Years 
Current Users: 5.3 ± 
2.8. 
Former Users: 4.7 ± 
3.0. 
Not Reported. Current Users: 2.7 ± 6.8. 
Former Users: 189 ±  163. 
Zeng et al., 
2016 
China Case-
Control 
170 Participants. 
Ketamine Users: n=51, 
M:F=29:22. Mean age = 
25.72±5.83. 
Methadone Users: n=60, 
M:F=36:23. Mean age = 
42.48±5.09. 
Control: n=60, 
M:F=30:30. Mean age = 
23.25±3.47. 
 
Reported 
Frequency: Days 
Per Week. 
Ketamine Users: 
6.09 ± 1.60. 
Not Reported. Ketamine Users: 
2.06 ±1.75. 
Participants self-reported 
abstinence for at least 24 
hours prior to study. 
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Zhang et 
al., 2018 
China  Case-
Control 
200 Participants. 
Ketamine (non heavy 
other drug) users8: n=286, 
M:F=186:100. Mean age = 
25.3±4.8. 
Ketamine (heavy other 
drug) users9: n=279, 
M:F188:91. Mean age = 
24.0±5.0. 
Control: n=261, 
M:F=128:133. Mean age = 
22.9±5.1. 
 
Reported 
Frequency: Days 
Per Month. 
Ketamine (non 
heavy other drug) 
users: 9.10 ± 10.72. 
Ketamine (heavy 
other drug) users: 
6.82 ± 9.69. 
Reported Time: 
Months. 
Ketamine (non 
heavy other drug) 
users: 77.68 ± 44.05. 
Ketamine (heavy 
other drug) users: 
81.35 ± 45.83. 
Ketamine (non 
heavy other drug) 
users: 3.47 ± 3.30. 
Ketamine (heavy 
other drug) users: 
3.49 ± 3.87. 
Not reported. 
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Memory is a complex domain, which encompasses a wide range of processes. 
There are a wide variety of tests employed to measure different aspects of memory. 
For this review, data from memory tasks will be broken down into declarative and 
working memory sections. 
 
Declarative Memory 
Declarative memory can be defined as memories that are consciously 
accessible for facts and events which have either personal or general relevance 
(Gazzaniga et al., 2002). Declarative memory, therefore, includes both episodic 
(memory for personally experienced events in their context) and semantic memory 
(memory for general information outside a personal context) (Tulving et al. 1998). 
These memories can be verbally reported and are also referred to as explicit memory 
(Gazzaniga et al., 2002). The cognitive tasks included in this review, which will be 
reported, are those that tap verbal learning and episodic memory, visual learning and 
episodic memory and semantic memory. 
 
Verbal Learning and Episodic Memory 
To assess verbal learning and episodic memory, studies most often utilise 
word list learning tasks (e.g. Rey Auditory Verbal Learning Test (RAVLT)) or a 
prose recall task (e.g. Prose recall subtest of the Rivermead Behavioural Memory 
Test) with immediate and delayed recall trails. Nine out of the 11 studies reviewed 
used measures of verbal learning to assess episodic memory (Chan, et al 2013; 
Cheng et al., 2018; Liang et al., 2013; Minseung Kim et al., 2016; Morgan et al., 
2009, 2010, 2012; Tang et al., 2013; Zhang et al., 2018) and eight studies reported an 
impairment in chronic ketamine users. Seven of these studies used drug naïve control 
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groups. Four of the studies used poly-drug user control groups. Four studies used ex-
ketamine user control groups (see table 3. for details).  
Six studies reported impairments in verbal learning and memory in chronic 
ketamine users when compared to drug naïve controls (Chan, et al. 2013; Liang et 
al., 2013; Morgan et al., 2010, 2012; Tang et al., 2013; Zhang et al., 2018). 
Furthermore, Liang et al. (2013) reported persisting impairments in ex-ketamine 
users. This was not found in all other studies employing ex-ketamine user controls 
(Morgan et al., 2009; 2010; Tang et al. 2013). Cheng et al., (2018) found that chronic 
ketamine users showed a similar level of impairment, on a word recall task, to a 
group of participants with a diagnosis of schizophrenia. Chan et al. (2013) reported a 
strong negative association with lifetime usage of ketamine (no. of years using 
ketamine) and performance on a task of verbal learning and episodic memory. 
Morgan et al., (2010) and Zhang et al., (2018) also reported that higher average doses 
of ketamine were related to poorer performance on a prose recall task. Thus, 
highlighting the possible impact that the degree of drug use has on cognitive 
impairment. Interestingly, both Zhang et al., (2018) and Morgan et al., (2012), 
reported a non-specific drug effect on verbal learning and memory. That is, 
impairments in verbal learning and memory were seen across other drug-using 
groups. Thus, highlighting the possible impact of other drug use in this domain and 
the problematic nature of using naturalistic populations. For instance, the difficulty 
attributing observed impairments to the drug ketamine when users frequently use 
other substances which may also impair this domain. In contrast to the above, 
Morgan et al., (2009), reported that frequent ketamine users showed no impairment 
on a task of prose recall.  
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Morgan et al., (2009; 2010) also used a Source Memory Task as an index of 
episodic memory, i.e. the awareness of when and where a stimulus was encoded.  
Both studies found no impairment in frequent ketamine users’ performance on 
source memory in comparison to controls.  That is, if frequent ketamine users 
recognised a word on the task, they were able to remember the contextual 
information surrounding it. However, in Morgan et al. 's (2009) study they reported 
that frequent ketamine users recognised fewer words on the Source Memory Task. 
This correlated with the spot the word scores (a measure of pre-morbid IQ) in 
frequent ketamine users. Thus, possibly suggesting that these deficits may, in part, be 
related to lower levels of pre-morbid IQ in the frequent ketamine user group studied.  
 
Visual Learning and Episodic Memory 
Seven out of the 11 studies reviewed used measures of visual learning to 
assess episodic memory (Chan, et al 2013; Cheng et al., 2018; Liang et al., 2013; 
Morgan et al., 2009, 2010; Tang et al., 2013; Zhang et al., 2018). Studies most often 
utilise figure tasks (e.g. Rey-Osterrieth Complex Figure) with immediate and delayed 
recall trails. In accordance with the data on verbal learning and episodic memory, six 
out of the seven studies using visual learning tasks found impairments in ketamine 
users (Cheng et al., 2018; Liang et al., 2013; Morgan et al., 2009, 2010; Tang et al., 
2013; Zhang et al., 2018).  Zhang et al., (2018) reported that shorter periods of 
abstinence from ketamine were associated with poorer performance on visual 
learning tasks. Thus, highlighting the need to investigate how abstinence affects 
performance in chronic ketamine users further. Conversely, Chan et al., (2013) found 
that their sample of ketamine users, although impaired on verbal learning and 
memory, were not significantly impaired on visual learning and memory. The 
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authors highlight that earlier literature in rats suggests that chronic exposure to 
NMDA-R antagonists affects verbal, but not visual learning and memory (Morris, 
Anderson, Lynch, & Baudry, 1986). However, another consideration are the 
differing levels of ketamine use that may be present across study populations. 
Indeed, Chan et al., (2013) required all participants to abstain from ketamine use 48 
hours before study participation. One possible implication of these findings is that 
impairments observed may be the result of acute residual effects of ketamine use. 
However, further study is warranted to explore this.  
 
Semantic Memory 
Meanings of words, knowledge and ideas are thought to be stored within the 
semantic memory system. Experimental methods which tap this memory often use 
semantic priming. Findings have shown that healthy individuals will generally show 
faster response times to target words (e.g. lemon) when they are followed by a prime 
word which is semantically related (e.g. orange). However, when a prime word that 
is not related (e.g. bin) follows the target word individuals generally show slower 
reaction times. The observed effect on reaction times is termed the semantic priming 
effect. 
Stefanovic et al., (2009) reported that long-term ketamine users did not differ 
from non-drug users in the semantic priming task. Furthermore, their study also 
reported that long-term ketamine users showed increased semantic priming (faster 
reaction times to related words) overall compared with the poly-drug user control 
group.  However, the authors suggest that this mainly reflected the very low priming 
levels in the poly-drug control group. The authors highlight that these results do not 
replicate previous research which indicated impairment in long-term ketamine users 
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semantic priming performance. Interestingly, participants in Stefanovic et al., (2009) 
on average used just under a gram of ketamine per session (0.99 g). However, all 
other studies in this review, that reported average amount of ketamine used per 
session, stated, on average, participants used several grams. One possible 
interpretation of this may be that although participants in the current study were 
long-term users of ketamine, they may need to take higher doses of the drug to see 
the same impairments reported in previous studies. 
 
Interim Summary 
In summary, the studies included in this review present a varied picture. 
Studies looking at verbal and visual learning with episodic memory are in line with 
previous research, with the majority of studies finding impairments in long-term 
ketamine users. However, these findings were not found in a task of semantic 
memory or the source memory task. Indeed, there was a general inconsistency in the 
tasks used across studies to measure these domains. The use of the prose recall task 
has been critiqued for its use in investigating episodic memory. Morgan & Riccelli et 
al., (2004) state that the task only requires participants to recall learnt information, 
and there is no component which requires participants to recall information specific 
to the encoding context. Thus, the different tasks employed may be measuring 
different component processes involved in declarative memory. Furthermore, several 
of the studies highlighted associations between drug use behaviour (frequency, 
abstinence, lifetime usage etc.) and performance on tasks. Patterns of drug use and 
how they relate to impairment warrant further investigation. Moreover, two studies 
reported non-specific drug impairments. Thus, highlighting the difficulty in 
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attributing observed effects to ketamine use when the population of users frequently 
use other illicit substances. 
 
Working Memory 
Working memory can be conceptualised as a system with the capacity to 
retain a limited amount of information over the short-term (maintenance) and the 
ability to perform mental operations on the information which is being stored 
(manipulation) (Gazzaniga et al., 2002). To date, working memory impairment in 
chronic ketamine users has been inconsistently reported. Nine of the reviewed 
studies considered working memory in the context of chronic ketamine use (Cheng et 
al., 2018; Liang et al., 2013; Minseung Kim et al., 2016; Morgan et al., 2009, 2010, 
2012; Tang et al., 2013; Zeng et al., 2016; Zhang et al., 2018). Eight studies included 
drug naïve control groups. Five studies used poly-drug user control groups. Four 
studies used ex-ketamine user control groups. Six of the nine studies considered here 
showed an impairment in chronic ketamine users as compared to the control groups 
(Minseung Kim et al., 2016; Morgan et al., 2009, 2010, 2012; Tang et al., 2013; 
Zeng et al., 2016).  
Three of the studies reviewed (Morgan et al., 2009; Morgan et al., 2010; 
Tang et al., 2013) reported that working memory deficits were specific to frequent 
ketamine users. Morgan et al. 's., (2010) one-year longitudinal study reported that, 
for the frequent ketamine user group, increases in self-reported ketamine use, over 
the year, were associated with an increase in errors on the spatial working memory 
task. The authors highlight that that there was no impairment in this task with healthy 
volunteers following an acute dose of ketamine (Morgan et al., 2010). Thus 
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indicating that this may be an effect which is confined to the frequent use of 
ketamine. 
Interestingly, Morgan et al., (2012) reported that chronic ketamine users and 
recreational poly-drug (including ketamine use) controls only showed impairment on 
the digit span backwards task and not the forwards part of the task (when compared 
to cannabis users, cocaine users and drug naïve controls). Thus, suggesting in this 
study that ketamine users specifically showed difficulties with manipulating (rather 
than merely storing) information in working memory, a problem which is also seen 
following acute ketamine use (Honey et al., 2004).  Thus maintenance of information 
in the working memory appears to be intact. 
Cheng et al., (2018) found that ketamine users, with persisting psychotic 
symptoms, performed similarly to a group of participants who had a diagnosis of 
schizophrenia across tasks of working memory. The authors suggest that this finding 
supports previous hypotheses that chronic ketamine users have a similar profile of 
cognitive impairments to individuals with diagnoses of schizophrenia (Morgan and 
Curran, 2006). 
Working memory functions were found to be intact in chronic ketamine users 
in three out of the nine studies considered (Cheng et al., 2018; Liang et al., 2018; 
Zhang et al., 2018). Liang et al., (2013) suggest one possible explanation for this 
inconstancy may be the differing levels of ketamine use across studies.  Indeed, 
Liang et al., (2013) reported that the ketamine users who participated in their study 
had relatively longer periods of abstinence and less median ketamine use per-month 
than Morgan et al., (2009). However, Zhang et al., (2018) reported that participants 
in their study showed comparative usage data (average quantity per session, lifetime 
usage) to the population in Morgan et al., (2009), but had significantly less median 
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use per month. Thus, perhaps indicating that days used per month may be negatively 
associated with the effects of long-term ketamine use on cognition.  
Tang et al., (2013) reported that depressive symptoms were modestly 
correlated with working memory in current ketamine users. Indeed, depressive 
symptomatology has been widely reported in chronic, daily ketamine users (Chan et 
al., 2013; Morgan et al., 2010; Morgan et al., 2009; Zhang et al., 2018). Given that 
depression has been related to implicit learning in poly-substance users (Stevens et 
al., 2007) and cognitive impairment is also widely found in depression (lee et al., 
2012) it is important to consider this as a possible confounding factor on cognitive 
performance. 
 
Interim Summary II 
In summary, the review has provided inconsistent results with regards to 
working memory.  Six of the nine studies reviewed have shown that chronic 
ketamine use is associated with deficits in working memory. Interestingly, both 
Liang et al., (2013) and Zhang et al., (2018), who found intact working memory 
functioning, reported that participants in their studies had a reduced level of 
ketamine use (monthly use and average amount of drug used per session) compared 
to the majority of studies that reported impairment. Indeed, level of drug use is likely 
an important factor in possible impairment. Given the naturalistic nature of the study 
sample, this is difficult to control. Further to this, there was an array of tasks used to 
assess working memory. Thus, differences in task difficulty may also impact study 
findings. Furthermore, only five of the nine studies utilised poly-drug user control 
groups. Thus, given the high level of poly-substance use in the ketamine using 
population, other drug use may have an impact on any observed impairments. 
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Executive Function 
Executive function comprises a broad range of cognitive processes that 
allows us to use our perceptions, our knowledge and task-orientated goals to inform 
the selection of actions and thoughts from a wide range of possibilities. Thus, giving 
us cognitive flexibility and letting us think, plan and act in ways that allow us to 
achieve goals and problem solve. A variety of standardized instruments are used to 
measure aspects of executive functioning. These include the Wisconsin Card Sorting 
Test, Stroop Test, and measures of verbal fluency. These tests assess specific 
components of executive functioning rather than executive functioning as a whole. 
Because of the broad range of processes involved in executive functioning, some 
measures will predominantly tap the planning component, such as the Stockings of 
Cambridge, or another measure may tap predominantly inhibition such as the Go/No-
Go task or the Hayling task. 
 
Fluency  
Five studies reported in this review used measures of verbal fluency (Chan et 
al., 2013; Liang et al., 2013; Morgan et al., 2009; Morgan et al., 2010; Tang et al., 
2013). All five of these studies used drug naïve control groups, three of the studies 
used ex-ketamine user comparison groups to assess post-abstinence effects, and two 
studies used poly-drug user control groups. 
Three out of the five studies reported impairment in verbal fluency in 
comparison to drug naïve controls (Chan et al., 2013; Morgan et al., 2010; Tang et 
al., 2013).  Morgan et al. 's (2010) 1-year longitudinal study reported a decline in 
semantic fluency over the course of the year. However, this decline was found in 
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both frequent and abstinent ketamine users. The authors note that this decline in 
performance was not correlated with a change in ketamine use and comment that it is 
unclear if this decline is being mediated by other factors, such as an increase in 
depressive symptoms across the two groups. 
Chan et al., (2013) reported that they found impairment in a task of verbal 
fluency, however not in a task of figural fluency (non-verbal tasks where persons are 
required to generate as many nonsense drawings or figures as possible within a 
limited time). The authors suggest that impairment in verbal fluency may be, in part, 
related to ketamine-induced damage to the left frontal cortex (Liao et al., 2011). 
Chan et al., (2013) continue to suggest, that the specific impairment in verbal 
fluency, and not figural fluency, reported in their study may be related to selective 
impairment of semantic memory as opposed to a general dysexecutive function. 
Two studies reported no impairments in chronic ketamine users in 
comparison to healthy drug control groups (Liang et al., 2013; Morgan et al., 2009). 
Again, Liang et al. 's., (2013) study utilised a group of participants who used less 
ketamine in an average session and took ketamine less frequently per month when 
compared to the other studies reviewed in this section. Thus, this may indicate dose-
related differences in performance on tasks of fluency.  
All studies reported in this section varied considerably in average days since 
last use of ketamine reported by the participants. For example, Chan et al. (2013) 
required participants to be abstinent for 48 hours before participating, whereas no 
other studies employed these controls. Thus, variations in performance, across this 
review, may also be impacted by a number of factors regarding drug use (e.g. period 
of abstinence, poly-substance use etc.)   
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Inhibition, Response Initiation and Selective Attention 
Response inhibition can be thought of as an executive function which 
involves managing behaviour, thoughts, attention and/or emotions to inhibit a strong, 
internal predisposition to respond to an external stimulus (Diamond, 2013). Measures 
of inhibition are derived from tests such as the Go/No-Go, Stop-Signal tasks, The 
Stroop Test and the Hayling test. However, it is important to note that these tests also 
tap other domains such as processing speed and verbal initiation. Thus, impairment 
on tasks may be the result of a component process, rather than the intended domain 
to be measured. 
Seven studies reported in this review used measures of inhibition (Chan et al., 
2013; Liang et al., 2013; Minseung Kim et al., 2016; Morgan et al., 2009; Tang et al., 
2013; Zeng et al., 2016; Zhang et al., 2018). Six of the studies used drug naïve 
control groups, three of the studies used ex-ketamine user control groups, and two 
studies used poly-drug user control groups. 
The findings present a mixed picture. Three studies reported impairments in 
the domain of inhibition (Minseung Kim et al., 2016; Tang et al., 2013; Zeng et al., 
2016). Zeng et al., (2016) reported that Ketamine users performed worse than the 
drug naïve control group on the stop-signal-go task (errors condition). Furthermore, 
ketamine users also performed significantly poorer than both methadone users and 
drug naïve controls in all conditions of the Stroop task. 
Tang et al., (2013) reported that ketamine users showed slower reaction time 
on the Stroop task in comparison to ex-ketamine users and drug naïve controls. 
Interestingly, impairment on the Stroop task was also found in a group of chronic 
pain patients who were being frequently treated with ketamine when compared to a 
group of patients who were not receiving long-term frequent- ketamine treatment 
	 44	
(Minseung Kim et al., 2016). However, it is important to note that Minseung Kim et 
al., (2016) recruited participants from a medical population of chronic pain patients. 
Further to this, the effects of other drug use were not considered in this study. Thus, 
the results of the study should be considered with caution.  
Four studies found no impairments on either the Stroop task (Chan et al., 
2013; Liang et al., 2013; Zhang et al., 2018) or the Hayling Task (Morgan et al., 
2009). Chan et al., (2013), Liang et al., (2013), and Zhang et al., (2018) all reported 
that ketamine users in their studies use the drug, on average, fewer days a month, 
than both Tang et al., (2013) and Zeng et al., (2016) (see table 3). Although, amount 
of ketamine used per session was similar between ketamine users in the majority of 
studies discussed in this section (Chan et al., 2013; Morgan et al., 2009; Tang et al., 
2013; Zeng et al., 2016; Zhang et al., 2018). Thus, perhaps indicating that frequency 
of use per month may have a greater impact on inhibition, initiation and selective 
attention than the amount used per session. 
 
Planning, Reasoning and Problem Solving 
Two of the studies considered in this review used the Wisconsin Card Sorting 
Test to assess set-shifting (Liang et al., 2013; Zhang et al., 2018) i.e. the 
measurement of how a person can flexibly switch tasks while being given changing 
schedules of reinforcement (Monchi et al., 2001). Both studies found no impairment 
in set shifting in frequent ketamine users. 
Two studies in this review used the Stockings of Cambridge (SOC). Based on 
the Tower of London task, this assesses spatial planning and provides an index of 
frontal lobe functioning (Morgan et al., 2009; 2010). Interestingly, Morgan et al. 
(2009) reported that the frequent ketamine user group were less likely to solve the 
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problems in the minimum number of moves when compared to all other groups in 
their study (infrequent ketamine users, ex-ketamine users, poly-drug control, drug 
naïve control). However, in their follow-up study, Morgan et al., (2010) found that 
frequent ketamine user’s performance had improved on the SOC Task. The authors 
suggest that these results may reflect practice effects, as the test only has one version. 
Furthermore, as the frequent ketamine user group performed particularly badly at 
bassline, they had a much greater potential to show improvement than the other 
groups who were observed in the study. 
 
Decision Making 
Substance misuse is often associated with impulsive decision making. 
Theoretically, this is because individuals who display impulsive traits may expect 
and also experience a higher level of reinforcement from substance use (Gullo et al., 
2014). This is further compounded by a diminished ability to limit substance use 
regardless of future negative consequences (Gullo et al., 2014). Risky and impulsive 
decision making is often measured using tasks such as the Iowa Gambling Task 
(IGT), delay discounting tasks, and behavioural risk-taking tasks including the 
Balloon Analogue Risk Task (BART). 
To date, research looking into the impulsivity of ketamine users is lacking. 
Out of the 12 studies reviewed, one study (Zeng et al., 2016) investigated this. The 
study used a case-control design to look at the differences in impulsivity and 
decision making across three groups: chronic ketamine users, chronic methadone 
users and drug naïve controls. The study used the Iowa Gambling Task (IGT) & 
Barratt's Impulsivity Scale to measure decision making and impulsivity respectively. 
The authors reported that methadone and ketamine users displayed scores indicating 
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high impulsivity on the Barratt’s Impulsivity Scale compared to the drug naïve 
control group. The authors highlight that these results replicate research on opioid 
user's self-reported impulsivity. Furthermore, evidence from longitudinal studies has 
suggested that impulsivity is a key factor in the early development of substance 
abuse (Sher et al., 1991; Finn, 2002). The authors suggest this may partially explain 
why ketamine users display continued patterns of use, however, often without 
displaying other signs of addiction.  
No significant differences were found between any groups on the Iowa 
Gambling Task (assessing decision making). The authors highlight that this finding 
is not consistent with some of the previous literature examining Iowa Gambling Task 
(Mukherjee and Kable, 2014) and suggest that studies investigating component 
processes which are utilised in the Iowa Gambling Task performance may highlight 
possible differences in ketamine users (Yechiam et al., 2005). 
 
Interim Summary III 
Executive functions perhaps pose one of the greatest challenges in measuring 
the impact of chronic ketamine use on cognition, due to the wide range of processes 
that make up the construct and the large number of tests that are used to assess it. 
This review has broken down executive function into four areas: planning, reasoning, 
problem-solving; inhibition, initiation, selective attention; fluency; and decision 
making. Across all four areas, there has been a wide range of inconsistencies in the 
findings. This may be, in part, a result of the range of tests employed to measure 
executive functions and the multiple domains tapped by each test. Thus, with a broad 
range of tests, the possibility of differing levels of difficulty is introduced. 
Additionally, it may also be partly explained by varying drug use across the 
	 47	
populations. Indeed, this is one of the most significant challenges when assessing this 
evidence. Given that there are many aspects of drug use (frequency, the amount used 
per session, lifetime usage etc.) comparing results across diverse samples presents 
many issues. Thus, further research examining these factors is warranted. 
 
Component Processes: Attentional Function and Processing Speed  
This section addresses the tasks used by researchers to look specifically at 
attentional function and processing speed. However, it is important to note that the 
functions measured by these tests are also important components to many of the 
other cognitive tests reviewed in this paper (e.g. to complete the Stroop test both 
attention and processing speed are important functions). Thus, highlighting the 
limited nature of considering these tests in isolated domains.  
Three of the tests included in this section of the review utilised Digit Symbol 
tasks as a measure of processing speed (Chan et al., 2013; Minseung Kim et al., 
2016; Tang et al., 2013).  Two of the three studies reported that frequent ketamine 
users showed impaired processing speed in comparison to control groups (Chan et 
al., 2013; Tang et al., 2013). Two of the studies reviewed used cognitive tests that tap 
sustained attention (Digit Vigilance test & Identification Task). Minseung Kim et al., 
(2016) reported that patients being treated in a long-term frequent ketamine group 
performed significantly worse on a measure of sustained attention (Controlled Oral 
Word Association Test) than the control group. In contrast to this, Chan et al., (2013) 
reported that there was no difference between sustained or selective attention (Digit 
Vigilance Test) in a group of current ketamine users when compared to drug naïve 
controls.  
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Interim Summary IV 
Tasks of general information processing were lacking in the studies 
considered in this review. However, it is important to note, that many of the tasks 
used to tap other domains, such as working memory, will also tap aspects of 
processing speed and attention. Indeed, this is a general consideration that needs to 
be taken into account across all sections of this review. 
 
Discussion 
Declarative Memory 
The body of work that has been examined in the current review has broadly 
mirrored previous research into the effects of chronic ketamine use on cognition. 
Cognitive testing in the domain of episodic memory generally indicated that chronic 
exposure to ketamine causes impairments in tasks of both verbal and visual learning 
on episodic memory. Further to this, it also mirrors the evidence provided in acute 
ketamine studies, which have been able to robustly show impairment in episodic 
memory functions following single doses of ketamine. One possible explanation for 
these findings comes from imaging studies. Evidence from structural magnetic 
resonance imaging (MRI) studies have indicated that, in chronic ketamine users, 
there is a significant reduction in the grey matter volume of the dorsal prefrontal 
cortex (PFC) (Liao et al., 2011), which has been suggested to potentially be, in part, 
a contributing factor in the impairment of episodic memory performance. 
Additionally, ketamine has been shown to cause neuronal death, which leads to a 
reduction in the grey matter volume in the PFC which can further explain the 
impairment seen in performance on memory tasks (Lebedev et al., 2004). However, 
the impairments discussed in this paragraph were not reported in a task of semantic 
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memory or a source memory task. This may highlight varying degrees of difficulty 
across tasks or that tasks may be tapping different aspects of memory function. Thus, 
further study is needed to continue exploring these domains. 
 
Working Memory and Executive Functions  
The body of work reviewed here presented an inconsistent picture regarding 
working memory and executive functions. This inconsistency in findings is in line 
with previous literature with some studies reporting impairments in working memory 
and executive functioning (e.g. Morgan, Mofeez, Brander, Bromley & Curran, 2004) 
and other studies finding no impairments (e.g. Newcomer et al., 1999). There are a 
number of proposed reasons for these inconsistencies. Morgan and Curran (2006) 
suggested that one reason may be due to the wide range of tests employed to measure 
these domains and thus potential differences in task difficulty.  Another explanation 
is that both working memory and executive functions may be particularly sensitive to 
the residual effects of acute ketamine use. Thus, the number of days that ketamine 
has been used in the previous month, and time since the last dose, may be significant 
factors which impact the performance of participants (Morgan et al., 2009). After a 
significant period of repeated, high doses of ketamine, NMDA receptor toxicity can 
occur. This may lead to a withdrawal state in these users which may, in part, explain 
variability in performance observed in the literature. That is, users may be in varying 
levels of withdrawal due to highly variable levels of drug use (e.g. frequency, the 
amount used per session etc.), which may then impact on their performance in tasks 
tapping working memory and executive functions. 
The papers included in this review have somewhat neglected both the 
domains of decision making and impulsivity. Given the links between impulsive 
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decision making and drug abuse, it would be important that this be taken up by future 
research in the context of examining a more comprehensive cognitive profile. 
 
Impairments in Ex-Ketamine Users  
Only one study out of four using ex-ketamine controls found persisting 
episodic memory impairments in ex-ketamine users (Liang et al., 2013). Indeed, 
previous research has yielded mixed results. A three-year longitudinal study found 
that semantic memory deficits were reversible in their study population (Morgan et 
al., 2006). However, episodic memory and attention deficits were not (Morgan et al., 
2006). Tang et al., (2013) suggested that the observed reversibility of cognitive 
impairment may be partly explained by evidence from animal models which have 
demonstrated the reversible neurotoxicity of NMDA-R antagonists (Jevtovic-
Todorovic et al., 2001). However, given that research to date is still conflicting it is 
essential that the consideration of other confounds be taken into consideration when 
assessing enduring impairments (e.g. effects of poly-drug use, the presence of 
depressed mood etc.). 
 
Methodological Issues 
Substance Use: The majority of studies included in this review reported on 
other drug use within their sample population. Several studies also used poly-drug 
user (without ketamine use) control groups. However, across the studies, there was a 
great deal of variation with regards to inclusion and exclusion criteria for poly-drug 
user groups. Three studies used urine samples to confirm group membership and two 
studies utilised hair samples to perform the same task. The remainder of the studies 
relied on self-reports from the study participants. It is likely that this method of data 
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collection will have a degree of measurement error which will reduce the reliability 
of information obtained. Given that ‘pure ketamine-only’ users are rare, i.e. most 
ketamine users also use other illicit substances, it is crucial that future research 
continues to control for poly-drug use. The use of biological analysis to confirm drug 
use appears to be the most effective way of achieving this at present. 
Studies included in this review reported varying levels of ketamine use 
among participants. Furthermore, findings indicated that longer lifetime usage (Chan 
et al., 2013), decreased length of abstinence before participation (Zhang et al., 2018) 
and increased dosage of ketamine (Morgan et al., 2010; Zhang et al., 2018) all 
negatively impacted performance on declarative memory tasks. Thus, the way people 
use ketamine (frequency, dosage, length of abstinence before the study, and lifetime 
use) and how this impacts on cognitive functioning are essential factors to explore in 
future research.  
Independent Group Design: A number of studies included in this review 
utilised independent group designs. Thus, researchers have attempted to create 
participant groups which are matched on a number of variables (e.g. educational 
attainment, pre-morbid IQ, drug use, age etc.). This is carried out for two primary 
purposes. Firstly, to treat groups as equivalents. Secondly, as an attempt to isolate the 
effect of the independent variable and reduce any effects of confounding variables. 
However, given the issues described regarding substance use, matching groups on 
this variable can be problematic. Indeed, using demographic details such as 
educational attainment may also be problematic in matching groups. 
Depressed Mood: Depression is also commonly associated with illicit 
substance use (Davis et al., 2008), including ketamine (Morgan and Curran, 2012). 
In the current review, nine out of the eleven papers reviewed included self-report 
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measures of depression (e.g. Beck Depression Inventory). Eight of the papers 
reported that frequent ketamine users have a higher level of depressive symptoms 
than control groups. Associations between illicit substance use and depression are 
most often explained by a causal relationship or shared etiological factors, such as 
genetic predisposition, which contribute to a pre-disposition to both disorders 
(Swendsen and Merikangas, 2000). However, studies exploring the relationship 
between long-term ketamine use and depression are lacking. Furthermore, depression 
in young adults has been shown to be associated with impairment in a range of 
cognitive domains (Castaneda et al., 2008). This includes executive dysfunction 
(Smith et al., 2006), attentional deficits (Mahurin et al., 2006) and short-term 
working memory impairments (Hill et al., 2004). Thus, it is essential that future 
research continues to consider the possible impact of depressed mood on any 
cognitive impairments observed in chronic ketamine users. 
Limitations of the Review Process: The main limitation of the review process 
relates to the process of dividing neuropsychological tests into specific cognitive 
domains. Although, given the diversity and breadth of data this was essential to 
allow a coherent description and comparison of research. It is important to consider 
that while any given cognitive assessment task may be designed to focus on one 
cognitive domain, any task will generally tap a number of systems which may reach 
across multiple cognitive domains (Wheeler et al., 1997).  Further to this, the various 
component process involved in the execution of tasks will also be shared across tests 
measuring different aspects of cognitive functioning (e.g. attention, reaction speed). 
Thus, isolating the effects of chronic ketamine use within single cognitive domains 
can be problematic. When looking at results on an individual (case by case basis), it 
is important to look at all tests of cognitive functioning in the broader context of the 
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whole battery of tests and any background information that you have on that 
individual. This is not possible when reviewing multiple studies. 
 
Clinical Implications   
This review has highlighted that chronic ketamine use has a number of long-
term effects on cognition which may not be reversible after cessation of ketamine 
use. Given the increasing use of the drug worldwide it is important that users can 
access information about the possible risks and harms that chronic use may bring. 
Furthermore, it is essential that dissemination of this information is done in a 
practical and accessible manner. Indeed, it is important that relevant healthcare 
professionals have access to this information so that they can provide accurate and 
relevant information to those that request it. 
 
Future Research 
As has been outlined in this review, research into the long-term effects of 
chronic ketamine use is still lacking. Numerous methodological complications make 
it difficult to generalise results across populations and findings are often inconsistent 
with previous literature. Thus, it is essential that there are continued longitudinal 
studies that will assess the effects of differing levels of ketamine use. In particular, 
studies should focus on the longevity of any observed impairments and whether 
observed impairments are reversible.  
 
Conclusions 
In conclusion, this review highlights that further research is needed to 
continue investigating the effects of chronic ketamine use on cognition. The papers 
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in this review suggest that chronic ketamine use may impair episodic memory which 
is in line with previous research. Studies looking at executive functioning and 
working memory have also mirrored previous research yielding inconsistent results. 
There are a number of methodological limitations when studying drug using 
populations which should be considered when designing future research. Thus, 
replication of findings is required alongside the continued development of research 
paradigms which investigate how drug use patterns impact cognition.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	 55	
References 
 
Aalto, S., Hirvonen, J., Kajander, J., Scheinin, H., Någren, K., Vilkman, H., ... & 
Hietala, J. (2002). Ketamine does not decrease striatal dopamine D 2 receptor 
binding in man. Psychopharmacology, 164, 401-406. 
 
Ballard, E. D., Ionescu, D. F., Voort, J. L. V., Niciu, M. J., Richards, E. M., 
Luckenbaugh, D. A., & Zarate Jr, C. A. (2014). Improvement in suicidal ideation 
after ketamine infusion: relationship to reductions in depression and anxiety. Journal 
of Psychiatric Research, 58, 161-166. 
 
Breier, A., Malhotra, A. K., Pinals, D. A., Weisenfeld, N. I., & Pickar, D. (1997). 
Association of ketamine-induced psychosis with focal activation of the prefrontal 
cortex in healthy volunteers. The American Journal of Psychiatry, 154, 805. 
 
Castaneda, A. E., Tuulio-Henriksson, A., Marttunen, M., Suvisaari, J., & Lönnqvist, 
J. (2008). A review on cognitive impairments in depressive and anxiety disorders 
with a focus on young adults. Journal of Affective Disorders, 106, 1–27.  
 
Clements, J. A., Nimmo, W. S., & Grant, I. S. (1982). Bioavailability, 
pharmacokinetics, and analgesic activity of ketamine in humans. Journal of 
Pharmaceutical Sciences, 71, 539-542. 
 
	 56	
Correll, G. E., Maleki, J., Gracely, E. J., Muir, J. J., & Harbut, R. E. (2004). 
Subanesthetic ketamine infusion therapy: a retrospective analysis of a novel 
therapeutic approach to complex regional pain syndrome. Pain Medicine, 5, 263-275. 
 
Davis, L., Uezato, A., Newell, J. M., & Frazier, E. (2008). Major depression and 
comorbid substance use disorders. Current Opinion in Psychiatry, 21, 14–18.  
 
Diamond, A. (2013). Executive functions. Annual Review of Psychology, 64, 135-
168. 
 
Finn, P.R.,2002. Motivation, working memory, and decision making: a cognitive 
motivational theory of personality vulnerability to alcoholism. Behavioral Cognitive 
Neuroscience Review, 1, 183–205. 
 
Gazzaniga, M. S., Ivry, R. B., & Mangun, G. R. (2002). The methods of cognitive 
neuroscience. Cognitive Neuroscience: The Biology of Mind, 2, 96-147. 
 
Gullo, M. J., Loxton, N. J., & Dawe, S. (2014). Impulsivity: Four ways five factors 
are not basic to addiction. Addictive Behaviours, 39, 1547-1556. 
 
Harris, E. W., Ganong, A. H., & Cotman, C. W. (1984). Long-term potentiation in 
the hippocampus involves activation of N-methyl-D-aspartate receptors. Brain 
Research, 323, 132-137. 
 
Hill, S. K., Keshavan, M. S., Thase, M. E., & Sweeney, J. A. (2004). Neuro- 
	 57	
psychological dysfunction in antipsychotic-naive first-episode unipolar psychotic 
depression. American Journal of Psychiatry, 161, 996–1003.  
 
Honey, R. A., Honey, G. D., O'loughlin, C., Sharar, S. R., Kumaran, D., Bullmore, 
E. T., ... & Fletcher, P. C. (2004). Acute ketamine administration alters the brain 
responses to executive demands in a verbal working memory task: an FMRI 
study. Neuropsychopharmacology, 29, 1203. 
 
Jansen, K. L. (1990). Ketamine–can chronic use impair memory. International 
Journal of the Addictions, 25, 133-139. 
 
Jevtovic-Todorovic, V., Wozniak, D. F., Benshoff, N. D., & Olney, J. W. (2001). A 
comparative evaluation of the neurotoxic properties of ketamine and nitrous 
oxide. Brain Research, 895, 264-267. 
 
Krystal, J. H. (2007). Ketamine and the potential role for rapid-acting antidepressant 
medications. Swiss Medical Weekly, 137, 215-216. 
 
Krystal, J. H., D’Souza, D. C., Karper, L. P., Bennett, A., Abi-Dargham, A., Abi-
Saab, D., ... & Charney, D. S. (1999). Interactive effects of subanesthetic ketamine 
and haloperidol in healthy humans. Psychopharmacology, 145, 193-204. 
 
Krystal, J. H., Karper, L. P., Seibyl, J. P., Freeman, G. K., Delaney, R., Bremner, J. 
& Charney, D. S. (1994). Subanesthetic effects of the noncompetitive NMDA 
	 58	
antagonist, ketamine, in humans: psychotomimetic, perceptual, cognitive, and 
neuroendocrine responses. Archives of General Psychiatry, 51, 199-214. 
 
Lapidus, K. A., Levitch, C. F., Perez, A. M., Brallier, J. W., Parides, M. K., 
Soleimani, L., ... & Murrough, J. W. (2014). A randomized controlled trial of 
intranasal ketamine in major depressive disorder. Biological Psychiatry, 76, 970-976. 
 
Lee, R. S., Hermens, D. F., Porter, M. A., & Redoblado-Hodge, M. A. (2012). A 
meta-analysis of cognitive deficits in first-episode major depressive disorder. Journal 
of Affective Disorders, 140, 113–124. 
 
Liao, Y., Tang, J., Corlett, P. R., Wang, X., Yang, M., Chen, H., et al. (2011). 
Reduced dorsal prefrontal gray matter after chronic ketamine use. Biological 
Psychiatry, 69, 42–48. 
 
Liao, Y., Tang, Y. L., & Hao, W. (2017). Ketamine and international 
regulations. The American Journal of Drug and Alcohol Abuse, 43, 495-504. 
 
Lynch, M. E., Clark, A. J., Sawynok, J., & Sullivan, M. J. (2005). Topical 
amitriptyline and ketamine in neuropathic pain syndromes: an open-label study. The 
Journal of Pain, 6, 644-649. 
 
Mahurin, R. K., Velligan, D. I., Hazleton, B., Davis, J. M., Eckert, S., & Miller, A. 
L. (2006). Trail making test errors and executive function in schizophrenia and 
depression. The Clinical Neuropsychologist, 20, 271–288.  
	 59	
 
Monchi, O., Petrides, M. Petre, V., Worsley, K., & Dagher, A. (2001). Wisconsin 
card sorting revisited: Distinct neural circuits participating in different stages of the 
task identified by event-related functional magnetic resonance imaging. The Journal 
of Neuroscience, 21, 7733-7741. 
 
Moore, K. (2004). A commitment to clubbing. Peace Review, 16, 459-465. 
 
Morgan, C. J., Curran, H. V., & Independent Scientific Committee on Drugs (ISCD). 
(2012). Ketamine use: a review. Addiction, 107, 27-38. 
 
Morgan, C. J., Mofeez, A., Brandner, B., Bromley, L., & Curran, H. V. (2004). 
Acute effects of ketamine on memory systems and psychotic symptoms in healthy 
volunteers. Neuropsychopharmacology, 29, 208. 
 
Morgan, C. J., Riccelli, M., Maitland, C. H., & Curran, H. V. (2004). Long-term 
effects of ketamine: evidence for a persisting impairment of source memory in 
recreational users. Drug & Alcohol Dependence, 75, 301-308. 
 
Morgan, C. J., Rossell, S. L., Pepper, F., Smart, J., Blackburn, J., Brandner, B., & 
Curran, H. V. (2006). Semantic priming after ketamine acutely in healthy volunteers 
and following chronic self-administration in substance users. Biological 
Psychiatry, 59, 265-272. 
 
	 60	
Morris, R. G. M., Anderson, E., Lynch, G. A., & Baudry, M. (1986). Selective 
impairment of learning and blockade of long-term potentiation by an N-methyl-D-
aspartate receptor antagonist, AP5. Nature, 319, 774. 
 
Mukherjee, D., & Kable, J. W. (2014). Value-based decision making in mental 
illness: a meta-analysis. Clinical Psychological Science, 2, 767-782. 
 
Newcomer, J. W., & Krystal, J. H. (2001). NMDA receptor regulation of memory 
and behavior in humans. Hippocampus, 11, 529-542. 
 
Newcomer, J. W., Farber, N. B., Jevtovic-Todorovic, V., Selke, G., Melson, A. K., 
Hershey, T.,& Olney, J. W. (1999). Ketamine-induced NMDA receptor hypofunction 
as a model of memory impairment and psychosis. Neuropsychopharmacology, 20, 
106-118 
 
Salvadore, G., & Singh, J. B. (2013). Ketamine as a fast acting antidepressant: 
current knowledge and open questions. CNS Neuroscience & Therapeutics, 19, 428-
436. 
 
Sher, K. J., Walitzer, K. S., Wood, P. K., & Brent, E. E. (1991). Characteristics of 
children of alcoholics: putative risk factors, substance use and abuse, and 
psychopathology. Journal of Abnormal Psychology, 100, 427. 
 
Smith, D. J., Muir, W. J., & Blackwood, D. H. R. (2006). Neurocognitive 
impairment in euthymic young adults with bipolar spectrum disorder and recurrent 
	 61	
major depressive disorder. Bipolar Disorders, 8, 40–46.  
 
Stevens, A., Peschk, I., & Schwarz, J. (2007). Implicit learning, executive function 
and hedonic activity in chronic polydrug abusers, currently abstinent polydrug 
abusers and controls. Addiction, 102, 937-946. 
 
Sunder, R. A., Toshniwal, G., & Dureja, G. P. (2008). Ketamine as an adjuvant in 
sympathetic blocks for management of central sensitization following peripheral 
nerve injury. Journal of Brachial Plexus and Peripheral Nerve Injury, 3, 22. 
 
Swendsen, J. D., & Merikangas, K. R. (2000). The comorbidity of depression and 
substance use disorders. Clinical Psychology Review, 20, 173–189.  
 
Thakurta, R. G., Ray, P., Kanji, D., Das, R., Bisui, B., & Singh, O. P. (2012). Rapid 
antidepressant response with ketamine: is it the solution to resistant 
depression?. Indian Journal of Psychological Medicine, 34, 56. 
 
Tulving, E. (1998). Neurocognitive processes of human memory. Wenner Gren 
International Series, 70, 263-283. 
 
United Nations Office on Drug Control, 2016. World Report 2016. United Nations, 
New York. Retrieved from: 
https://www.unodc.org/doc/wdr2016/WORLD_DRUG_REPORT_ 2016_web.pdf. 
	 62	
 
Verdejo-García, A., Lawrence, A. J., & Clark, L. (2008). Impulsivity as a 
vulnerability marker for substance-use disorders: review of findings from high-risk 
research, problem gamblers and genetic association studies. Neuroscience & 
Biobehavioral Reviews, 32, 777-810. 
 
Wheeler, M. A., Stuss, D. T., & Tulving, E. (1997). Toward a theory of episodic 
memory: the frontal lobes and autonoetic consciousness. Psychological bulletin, 121, 
331. 
 
Yechiam, E., Busemeyer, J. R., Stout, J. C., & Bechara, A. (2005). Using cognitive 
models to map relations between neuropsychological disorders and human decision-
making deficits. Psychological Science, 16, 973-978. 
 
Young, S. N. (2013). Single treatments that have lasting effects: some thoughts on 
the antidepressant effects of ketamine and botulinum toxin and the anxiolytic effect 
of psilocybin. Journal of Psychiatry & Neuroscience, 38, 78. 
 
Zarate, C. A., Singh, J. B., Carlson, P. J., Brutsche, N. E., Ameli, R., Luckenbaugh, 
D. A., & Manji, H. K. (2006). A randomized trial of an N-methyl-D-aspartate 
antagonist in treatment-resistant major depression. Archives of General 
Psychiatry, 63, 856-864. 
 
 
 
 
 
	 63	
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	 64	
Part 2: Empirical Paper 
 
Comparing the Effects of Ketamine and Lidocaine on 
Mood, Subjective Drug Effects, and Pain 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	 65	
Abstract  
Aim: To explore the effects of sub-anaesthetic intravenous infusions of 
ketamine compared to lidocaine in chronic neuropathic pain patients. The study 
examined the effects of ketamine treatment on mood, subjective drug effects and 
pain. The association between pain and mood was also evaluated. 
Method: A between subject’s design was used to compare patients receiving 
ketamine treatment (n=24) with a control group receiving lidocaine treatment (n=34) 
over four-time points (baseline, mid-infusion, post-infusion and one-week follow-
up). Mood was assessed using the Hospital Anxiety and Depression Scale (HADS), 
Patient Health Questionnaire-2 (PHQ-2) and an 11-point Numerical Rating Scale 
(NRS). Pain was assessed over three indices (intensity, distress and interference) 
using 11-point NRS and similar scales were used for patient ratings of subjective 
drug effects. 
Results: Both ketamine and lidocaine treatments yielded similar reductions 
in pain intensity at the one-week follow-up. Ketamine provided a greater reduction in 
pain intensity during the infusion. Subjective drug effect scales indicated that the 
ketamine treatment group felt significantly higher, felt a stronger sensation of drug 
effect, and liked the drug effect more than the lidocaine group. Data from mood 
measures were inconclusive. PHQ-2 and depression NRS showed reductions in 
scores of depression at the one-week follow-up for both treatment groups. However, 
HADS depression scores showed no significant differences. HADS anxiety data 
indicated that both ketamine and lidocaine groups showed significant reductions in 
anxiety at one-week follow-up. Further correlational analysis indicated a relationship 
between a reduction in both pain intensity and interference scores (baseline and one-
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week follow-up) with a reduction in HADS anxiety scores for the ketamine treatment 
group. 
Conclusion: The findings support previous literature showing the efficacy of 
ketamine treatment for chronic neuropathic pain. Results indicated that participants 
experienced the acute reinforcing effects of ketamine (feeling high and liking the 
drug effect) but did not want more of the drug. This may indicate a reduced abuse 
potential in the chronic pain population. Findings also indicated that ketamine did 
not produce anti-depressant effects in patients with chronic neuropathic pain. 
Therefore, that the rapid-acting anti-depressant effects found in populations of 
treatment-resistant depressed patients may not extend to those with chronic pain.   
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1. Introduction 
1.1 Overview 
Chronic neuropathic pain diagnoses have been increasing over the past three 
decades (Fayaz et al., 2016). Neuropathic pain is the result of lesions or damage to 
the somatosensory nervous system (Treede et al., 2008). This damage can cause 
alterations in the structure and/or function of the nervous system which may lead to 
pain occurring spontaneously or in response to innocuous stimuli (Niesters et al., 
2014). A number of neurochemical processes are thought to underlie the 
development and maintenance of neuropathic pain causing peripheral and central 
sensitization (Treede et al., 2008). Symptoms include an increase in painful response 
to ordinarily innocuous and normally painful stimuli, enhanced temporal summation 
and spontaneous pain. Treatment for neuropathic pain is varied and generally 
involves a trial and error approach. Anti-depressants and anti-epileptics are used as 
first-line drugs. However, treatment efficacy (‘adequate’ pain relief) for these 
medications is limited with only 30-40% of patients responding. The remainder of 
patients either show very limited or no response (Dworkin et al., 2010, Finnerup et 
al., 2005).  
 
1.2 The N-Methyl-D-Aspartate receptor 
Recent research has implicated the N-Methyl-D-Aspartate receptor (NMDA-
R) in the development and maintenance of chronic pain. During chronic pain states, 
the NMDA-R is activated and up-regulated in the spinal cord (central sensitization) 
(Schwartzman et al., 2001). This causes an increased responsiveness in the pain 
pathways within the central nervous system leading to the symptoms of neuropathic 
pain described above (Sigtermans et al., 2009). Considering this relationship, 
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NMDA-R antagonists could theoretically have an important role in the treatment and 
management of neuropathic pain. 
 
1.3 Ketamine’s Analgesic and Anaesthetic Use 
Ketamine, a potent NMDA-R antagonist, produces strong analgesia in 
patients with neuropathic pain states when given at sub-anaesthetic doses. This effect 
is presumed to work via the direct inhibition of NMDA-Rs. However, other 
mechanisms, such as increases in descending inhibition or anti-inflammatory effects 
at central sites, may also contribute. NMDA-R antagonists such as ketamine may 
also reverse central sensitization and alter neuroplasticity (Azari et al. 2012). There is 
now a growing body of evidence that suggests ketamine is efficacious in the 
treatment of both neuropathic pain and post-operative pain (Hocking & Cousins, 
2003; Nourozi et al. 2010; Finch et al., 2009). 
Ketamine has a long history of use as an approved anaesthetic agent in 
children and adults for both diagnostic and surgical procedures (Lanning and 
Harmel, 1975). In anaesthesia, ketamine is usually administered intravenously. 
However, administration of the drug may also be carried out subcutaneously, 
intramuscularly, intradermally, intranasally, intrarectally, or orally. Although 
dissociative reactions have been associated with its use in anaesthesia, ketamine 
continues to be an advantageous anaesthetic because of its short half-life (approx. 
180 mins) and lack of respiratory depression (Celmens et al., 1982). Single infusions 
of ketamine are well tolerated. However, transient side effects of ketamine in clinical 
studies include psychotomimetic symptoms (e.g. hallucinations, delusions), memory 
deficits, panic attacks, nausea, and somnolence. These effects typically reduce once 
infusions have stopped and completely subside within two hours (Aan Het Rot et al., 
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2012, Blier et al., 2012). For the last half-century, ketamine has been shown to have 
a robust safety profile and has been administered, in clinical practice, to millions of 
people worldwide. (Lahti et al., 2001; Corrsen et al., 1988; Reich and Silvay, 1989; 
White et al., 1982). Indeed, ketamine is on the WHO’s list of essential medicines. 
 
1.4 Assessment of Pain in Research 
Several guidelines exist with regards to measuring the efficacy and safety of a 
drug in the management of chronic pain. The Initiative on Methods, Measurement, 
and Pain Assessment in Clinical Trials (IMMPACT) aims to aid the implementation 
of clinical trials via the development of reviews and guidelines that focus on the 
design and execution of research in the field. IMMPACT guidelines recommend 
when assessing the efficacy of treatment for chronic pain that six core outcome 
domains are considered: pain, physical functioning, emotional functioning, 
participant ratings of improvement and satisfaction with treatment, symptoms and 
adverse events, and participant disposition (Turk et al., 2003). These guidelines have 
been taken into consideration while designing the current study.  
 
1.5 Recreational Use of Ketamine 
A different population using the drug ketamine do so ‘recreationally’ because 
they value its psychotomimetic and other effects. This population is varied, with a 
minority using the drug daily and a majority using much less often, for example, only 
at music festivals. Recreational use of ketamine has increased since the turn of the 
century (Moore, 2004) and an additional number of reported risks have come to light 
as a result. Heavy use of the drug is associated with bladder and renal complications 
as well as memory deficits. It is important to note that due to the repeated exposure 
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to large doses of ketamine and the high frequency of abuse of other substances in this 
population it is not possible to directly extrapolate these risks to clinical (pain 
management) populations. In clinical settings, ketamine has proven to be well 
tolerated by patients. Furthermore, heavy recreational users of ketamine often use 
grams of the drug every day. However, in medical settings milligrams are used more 
commonly once a month. 
 
1.6 Ketamine’s Reinforcing Properties 
Research examining the reinforcing or dependence-forming properties of 
ketamine is currently limited. Pre-clinical findings, across a number of behavioural 
paradigms, indicate that ketamine may share a number of properties with other 
dependence-forming substances. Studies have shown that ketamine produces 
conditioned place preference (Layer et al. 1993), and is self-administered by rats and 
primates (Marquis et al.1989; Winger et al. 1989). Ketamine substitutes for ethanol 
in drug discrimination paradigms with rats (Shelton, 2004 & Harrison et al. 1998) 
and alcohol-dependent humans show enhanced NMDA function (Krystal et al. 
2011). Further, Ketamine has been shown to produce similar subjective drug effects 
to ethanol in recently detoxified alcoholics (Krystal et al., 1998). Morgan et al. 
(2004) found an inverted U-shaped dose-response curve when healthy, ketamine-
naïve volunteers were asked to rate how much they ‘liked' the drug and wanted more 
of it when sub-anaesthetic doses (0.4mg/kg and 0.8mg) or placebo was infused 
intravenously. Results showed that both groups given ketamine liked the drug effects 
and wanted more of both doses in the early phase of the infusion.  However, for the 
high dose group, these ratings showed a significant reduction towards the end of the 
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infusion. Conversely, the low dose group continued to report liking the drug effects 
and wanting more of the drug.  
  
1.7 Ketamine’s Antidepressant Properties 
Recent evidence suggests that ketamine also possesses potent antidepressant 
properties (see Abdallah et al. 2015 for review). Major depressive disorder (MDD) is 
a significant global health concern, affecting millions of people and thus having 
severe socioeconomic and health consequences (Kessler et al., 2003). Currently, the 
use of antidepressant treatment in patients with MDD has proven to be unsatisfactory 
for a significant proportion (around a third) of those treated. Indeed, relapses, low 
remission rates and continuing low-level symptomatology are common and can lead 
to persistent functional impairment. Further, there is a wide acceptance that both 
tricyclic and SSRI antidepressant medications require a lag period of several weeks 
before any improvement in mood and well-being are experienced. Thus, there is a 
clear need for a treatment that has rapid-acting antidepressant properties. Ketamine 
has been of particular interest because of its rapid antidepressant effects (Berman et 
al., 2000). Berman et al. (2000) found that treatment refractory MDD patients 
showed a robust antidepressant effect within 4 hours of a sub-anaesthetic dose of 
ketamine which subsided within one-to-two weeks of the initial infusion. These 
antidepressant properties of ketamine have been replicated several times (see 
Abdallah et al. 2015 for a review) including randomized controlled trials (RCTs) 
(Berman et al., 2000; Murrough et al., 2013; Zarate et al., 2006; Valentine et al., 
2011). Furthermore, meta-analyses have shown the rapid antidepressant effects of 
ketamine to be robust relative to saline controls. Additionally, ketamine has been 
found to be more effective than control placebo treatments with active side-effect 
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profiles in order to make the blinding component of the study more robust (Newpoer 
et al., 2015; Caddy et al., 2014; Fond et al., 2014; McGirr et al., 2015; Romeo et al., 
2015). 
 
1.8 Co-Morbid Depression and Chronic Pain 
Depression and depressive-like symptoms are often found co-morbidly in 
people who have chronic pain (Banks and Kerns, 1996). There are a number of 
theories that have attempted to explain the co-occurrence of chronic pain and 
depression, yet the relationship between the two remains unclear. Some theories 
conceptualize the two as distinct, unrelated conditions, while other theories have 
suggested that regarding psychology or biology they are closely linked. Early 
theories suggested that chronic pain may be the result of a conversion of conscious or 
unconscious psychological distress into pain (psychosomatic) (e.g. Blumer and 
Heilbronn 1982). However, research demonstrating changes in the central nervous 
system of those with chronic pain has provided clear evidence against this model 
(Tracey and Mantyh 2007; Turk and Salovey 1984; Crombez et al., 2009). Bank’s 
and Kern’s (1996) diathesis-stress model postulates that some individuals may be 
more likely to develop depression due to an increased sensitivity to particular 
stressors. This increased sensitivity may be the result of genetic vulnerability or 
environmental factors. Thus, this model predicts that chronic pain would be a 
stressor which increases the likelihood of an individual developing depression. More 
recently, evidence from the field of neuroscience has highlighted the efficacy of an 
emotion regulation model. Linton and Bergbom’s (2011) model considers the 
interaction of pain and depression in relation to other cognitive factors such as 
catastrophizing and emotion regulation. Firstly, the authors highlight the central role 
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of catastrophizing in models of both pain and depression thus signifying an important 
link. Secondly, how depression and pain both act as significant emotional stressors. 
The model states that episodes of pain induce catastrophic thinking which leads to an 
increased strain on an individual’s emotional regulation system. Successful 
regulation of this leads to coping, while negative behavioural emotional regulation 
leads to increased negative affect, pain, and mood-related disability.  However, 
current theories still contend with integrating neuroscience and psychological 
theories of co-morbid pain and depression. Indeed, there is a risk of not representing 
the extent to which the common pathways and neurotransmitter systems impact on 
the experience and development of chronic pain and depression.  
Williams and Schafer (2016) conducted a review of longitudinal studies 
looking at the relationship between pain and depression.  This highlighted evidence 
which suggests the presence of depression at baseline testing leads to worse 
outcomes in chronic pain. Thus, the detection of depression and treatment of any 
mood disorder alongside pain management may substantially enhance outcomes. 
However, reliable evidence for existing models of chronic pain and depression are 
lacking (Williams and Schafer, 2016). Indeed, assessing the emotional functioning of 
patients who present with chronic pain has proven difficult because of the overlap 
between symptoms of depression (fatigue, memory and concentration deficits, libido, 
appetite or weight changes) and those of chronic pain and or the associated side 
effects of some of the medications used to treat chronic pain. Further to this, many 
measures used to screen or diagnose depression may have poor validity within the 
chronic pain population (e.g. Pincus and Williams, 1999; Morley et al., 2002; Shafer, 
2006).  
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1.9 Rationale for the Current Study 
Given ketamine's efficacy as a treatment for chronic pain, alongside its rapid-
acting anti-depressant effects, we are interested in ketamine's effects on mood in the 
chronic neuropathic pain population. If patients treated with ketamine show 
significant improvements, relative to controls, on measures of mood, this might 
tentatively indicate that ketamine’s anti-depressant properties extend to chronic 
neuropathic pain patients. Furthermore, in both healthy volunteer and animal studies, 
ketamine has been shown to share a number of properties with other dependence-
forming drugs. Thus, we hope to gain an insight into how a chronic pain population 
responds to the drug, how well tolerated it is at the doses given and how much the 
patients enjoy or want more of the drug. This is important, concerning its use 
clinically, as it may indicate abuse potential, the practicality of use, and adverse 
effects in this population. Through this research, we also hope to add to the growing 
evidence base in the use of ketamine in a chronic pain setting.  
 
1.10 Hypotheses 
Based on the literature regarding ketamine’s anti-depressant properties (see 
Abdallah et al., 2015 for review), and the strong link between depression and chronic 
pain (Banks and Kerns, 1996), we predict that patients receiving ketamine treatment 
will show a greater improvement on measures of depressed mood than the lidocaine 
group. 
Based on previous research we predicted that the ketamine group would 
experience more subjective drug effects than the lidocaine group. In particular, they 
will have higher ratings of perceptual distortions, feeling high, wanting more of the 
drug, and intensity of drug effect (Morgan et al., 2004). 
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With regards to chronic pain, based on the work discussed above (Hocking & 
Cousins, 2003; Nourozi et al., 2010 and Finch et al., 2009) we predicted that we will 
observe a reduction in pain both at the acute stage (during treatment) and at the one-
week follow-up stage for both ketamine and control group patients treated with 
lidocaine. 
Further exploratory within-group correlations for pain measures and mood 
measures will be carried out looking for correlations between pain relief and change 
in depression. 
  
1.11 Aims 
This, primarily exploratory study had three aims. First, it sought to explore 
the effects of sub-anaesthetic doses of intravenous (IV) ketamine on the mood of 
patients with chronic neuropathic pain. Second, was to assess the acute effects of low 
sub-anaesthetic IV ketamine on subjective drug effects such as enjoyment, wanting 
more of the drug and feeling high. Third, it aimed to observe the effect of ketamine 
on pain both acutely and at a one-week follow-up.  
 
2. Method 
2.1 Power Analysis  
Power analysis for this study was informed by Coyle and Laws (2015). This 
meta-analysis found large effect sizes for the acute effects of single infusions of 
ketamine on depressed mood. Assuming equal group sizes, the power calculation 
was carried out on "G*Power 3" computer program (Faul, Erdfelder, Land, Buchner, 
2007), specifying alpha=5% and desired power =80%. The effect size was 
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conservatively estimated down from large to medium and with a predicted sample 
size of 40 (per-group) we calculated a total power of 0.87. 
 
2.2 Joint Thesis 
This thesis is part of a joint research project and was completed together with 
a fellow trainee clinical psychologist, Catherine Trotman (Trotman, 2018). See 
appendix 1. for further details of contributions made by each trainee. 
 
2.3 Ethics 
The study was approved by the South Central Berkshire NHS Research 
Ethics committee (see appendix 2). All participants provided written informed 
consent (see appendix 3.). 
 
2.4 Participants and Design and Study Site 
A between-within subjects quasi-experimental design was used to compare 
patients receiving ketamine treatment with those receiving the sodium channel 
blocker lignocaine. Lignocaine was chosen as a comparison drug for several reasons. 
Firstly, it has a well-documented efficacy and safety profile within the chronic pain 
population (Hocking & Cousins, 2003; Nourozi et al., 2010; Finch et al., 2009). 
Secondly, patients at the UCLH pain management centre are regularly treated with 
lignocaine for the management of chronic neuropathic pain, thus provide an easy 
group to recruit from in a natural experiment. Thirdly, lignocaine has not been shown 
to have antidepressant properties in populations of depressed patients. Thus, it would 
provide a good comparison to ketamine with regards to its effects on depressive 
symptomatology within the chronic pain population. Fourthly, lignocaine is not 
	 77	
abused recreationally, thus would provide a good comparison for the reinforcing 
effects of ketamine. 
A convenience sample of participants was identified using the database from 
the study site. Researchers attempted to contact patients receiving ketamine or 
lidocaine infusions between February 2018 and May 2018. Those who were 
interested in participating were emailed a participant information sheet (see appendix 
4.).  Those who agreed to participate in the study were then scheduled for testing at 
the same time as their infusion of ketamine or lidocaine. All participants provided 
written informed consent. 
Inclusion criteria were men and women aged 18-70 years who were native 
English speakers. Participants had moderate to severe chronic neuropathic pain and 
had been deemed by their consultant to require IV lignocaine or ketamine to manage 
their pain. Patients were excluded if they had a suspected allergy to ketamine, 
diagnosis of psychiatric illnesses, a record of serious head injury, a record of learning 
disability, were pregnant or breastfeeding, or were unable to provide informed 
consent. 
The study site is a nationally recognised centre of excellence for people with 
acute chronic pain. The service comprises of a multi-disciplinary team of doctors, 
nurses, physiotherapists and psychologists. The service receives nationwide referrals 
for patients who have been unable to manage their pain locally alongside providing 
services locally. The service is one of several centres nationwide that prescribes 
ketamine to manage chronic pain and also provides other specialist interventions 
including systemic drug treatment, intravenous drug infusions, peripheral and central 
nerve blocks, radio frequency lesioning and spinal implants. They also also provide 
information and access to TENS machines and acupuncture. 
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2.5 Measures  
2.5.1 Mood 
 The Hospital Anxiety and Depression Scale (HADS) (Zigmond and Snaith, 
1983) was employed as the primary measure of depression. Additionally, the 2-item 
Patient Health Questionnaire depression module (PHQ-2) and a depression 
Numerical Rating Scale (NRS) (described in 2.5.3) were chosen because of their past 
use in studies exploring the antidepressant and reinforcing effects of ketamine. 
Further, both of these measures were brief (<2 items) and did not include items that 
report on somatic symptoms. 
The HADS is a self-report measure developed to identify depression and 
anxiety in non-psychiatric hospital settings (see appendix 5). The measure contains 
seven items in an anxiety subscale and seven items in a depression subscale. The 
HADS does not include items measuring somatic symptoms, such as insomnia, 
common in many other questionnaires measuring anxiety and depression. The HADS 
has been studied rigorously across a wide range of populations. Bjelland, Dahl, Haug 
and Neckelmann (2002) conducted a review of 747 studies to assess the validity of 
the HADS. They reported that alphas for the internal reliability of the anxiety 
subscale were within the range of 0.68 to 0.92 (mean 0.83). With regards to the 
depression subscale, the alphas ranged from 0.76 to 0.90 (mean 0.82). Their review 
also demonstrated that the HADS had a similar sensitivity to other widely used 
measures which assess mood and anxiety, such as the Beck Depression Inventory 
and the General Health Questionnaire. Thus, the reviewers concluded that the 
concurrent validity of the HADS is good to very good.  
The PHQ-2 (see appendix 5.) is a brief version of the 9-item Patient Health 
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Questionnaire depression module (PHQ-9). The PHQ-2 asks recipients to report on 
the frequency of depressed mood and anhedonia over the past two weeks scoring 
each as 0 ("not at all") to 3 ("nearly every day"). Kroenke et al. (2003) conducted a 
study on the validity of the PHQ-2 on a sample of 6000 patients. The short-form 
General Health Survey in conjunction with participant reported sick leave and 
symptom-related impact of day-to-day functioning was used to assess construct 
validity. An independent structured mental health professional interview, in a sample 
of 580 patients, was used to assess criterion validity. The study found that a PHQ-2 
score of >3 had a sensitivity of 83% and a specificity of 92% for major depressive 
disorder. The researchers concluded that overall the construct and criterion validity 
of the PHQ-2 make it a good measure of depression screening. 
 The PHQ-2 was adapted in this study to ask participants to report the 
frequency of depressed mood over the past week, rather than two weeks in the 
original (Kroenke et al., 2003). This change was implemented to ensure that 
participants were only reporting on the period between their infusion and the 1-week 
follow-up. 
 
2.5.2 Pain Intensity, Pain Distress and Pain Interference 
Participants will be asked to rate their pain on three 11-point (0-10) NRS (see 
appendix 6.). The pain intensity scale asked ‘how intense is your pain right now' with 
0 being anchored with the label of no pain and 10 being anchored with the label 
extremely intense pain. Participants would then circle the appropriate number on the 
numbered line using a pen. Alternatively, participants could also verbally report their 
response to the researcher.  Similar 11-point scales were used to measure pain 
distress, with the anchor of 0 being ‘not distressing' and the anchor of 10 being 
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‘extremely distressing'. The anchors for the 11-point pain interference scale were 0 
‘does not interfere' and 10 ‘interferes with everything'. As above, participants either 
circled the appropriate answer or responded verbally which was followed by the 
researcher recording their answer. 11-point NRS were chosen as research suggests 
that they are as reliable and valid for pain ratings as Visual Analogue Scales (VAS), 
11-point box scales and 101-point numerical rating scales for both acute and chronic 
pain (Jensen, Karoly, & Braver, 1986; Jensen, Karoly, O’Riordan, Bland, & Burns, 
1989). In addition to this, research has suggested that individuals prefer NRS over 
VAS (Price, Patel, Robinson, & Staud, 2008). Furthermore, NRS have been shown to 
have similar sensitivity to VAS (Bolton & Wilkinson, 1998; Bone et al., 2002; 
Breivik et al., 2000; Changues et al., 2010). It is not possible to determine internal 
consistency for these NRS as they are single item measures.  
 
2.5.3 Subjective Rating Scales 
 A subjective drug effects scale containing 11 items consisting of an 11-point 
NRS (Curran & Morgan, 2000) was employed (see appendix 7.).  Effects were split 
into four broad categories: i) Bodily Symptoms (dizziness, drowsiness, nausea), ii) 
Cognitive/Mood Symptoms (mental confusion, depression), iii) Perceptual 
Symptoms (visual distortions, out of body experience) and iv) Reinforcing Drug 
Effects (liking the drug, disliking the drug, feeling high, feeling a drug effect). All 
were measured using 11-point NRS with the anchor of 0 labelled ‘not at all', and the 
anchor of 10 labelled ‘extremely'. Participants would then either circle the 
appropriate number on the numbered line using a pen or verbally report their 
response to the researcher who would then record it.  
 
	 81	
2.5.4 Alcohol Use 
The Alcohol Use Disorders Identification Test (AUDIT) was used to index 
the participant's alcohol use (see appendix 8.).  The AUDIT is a 10-item, self-
administered questionnaire that was developed to detect patterns of heavy alcohol 
use (Babor et al., 2001). Items are rated on a five-point Likert scale (0-4) with higher 
scores reflecting hazardous alcohol use. The AUDIT employs a cut-off score off 
eight which indicates hazardous alcohol use. The AUDIT has good reliability and 
validity (Babor et al., 2001). 
 
2.5.6 Demographic Details 
Participant age and gender were recorded (see appendix 8.). Participants were 
also asked to state the highest level of education they had attained: GCSE or age 16 
equivalent, A-Level or age 18 equivalent, undergraduate or equivalent, post-graduate 
or equivalent. 
 
2.6 Procedure  
2.6.1 Baseline 
When participants arrived at the pain clinic for their appointment, they were 
greeted by researchers and asked to provide informed consent. Participants were 
asked to complete initial baseline measures about current depressive 
symptomatology (HADS and PHQ-2, depression NRS), three NRS assessing 
different indices of pain (intensity, degree of distress, and degree of interference in 
functioning caused by the pain). Participants were also asked to complete the 
subjective effects NRS bodily symptoms (dizziness, drowsiness, nausea), 
cognitive/mood symptoms (mental confusion, depression), and perceptual symptoms 
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(visual distortions, out of body experience). Participants were not asked to complete 
the reinforcing drug effects NRS at baseline. Following completion of these 
measures, researchers informed the medical staff that the patient was ready for their 
infusion and participants were admitted to the ward for treatment. 
 
2.6.2 Infusion 
Ketamine infusions typically lasted for around 30 minutes, while lidocaine 
infusions lasted between one to three hours. Participant’s mid-infusion time-point 
and treatment dosage were calculated at the beginning of each infusion. Protocols for 
treatment dose at the study site were 0.5mg per kg of body weight for ketamine and 
2-to-3mg per kg of body weight for lidocaine.  A number of factors dictate whether a 
patient is prescribed lidocaine or ketamine including the patient’s medical history 
and current medications being used. Lidocaine is typically used as the first line 
infusion treatment at the study site. If patients show no or limited response to 
lidocaine they will then be prescribed ketamine. However, if patients have any 
history of heart disease, cardiac arrhythmias, recent myocardial infarction or are 
deemed to be high risk for cardiac complications they would not be eligible for 
lidocaine treatment and would be prescribed ketamine in the first instance. 
 
2.6.3 Mid-infusion 
At the mid-point of their infusion participants were asked them to complete 
the three pain NRS (intensity, distress and interference) and the full subjective 
effects NRS battery.  
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2.6.4 Post-Infusion 
Immediately after infusions were finished participants completed the three 
pain NRS, full subjective effects NRS battery, AUDIT and the highest level of 
education attained questionnaire. They were then given the opportunity to ask any 
further questions and a time was arranged to carry out the one-week follow-up phone 
call. 
 
2.6.5 One-Week Follow-Up 
One-week following each participant’s infusion they were contacted by 
telephone. Participants were given the opportunity to answer any questions, and then 
the same set of measures completed at baseline were repeated remotely. See table 1. 
for a summary of the procedure. 
Table	1	Summary	of	Procedure	Depicting	Which	Tests	Were	Carried	out	at	Each	Time-Point	
Prior to 
infusion/baseline 
Infusion Mid-infusion Post-infusion 1-week follow-up 
Pain NRS n/a Pain NRS Pain NRS Pain NRS 
HADS n/a HADS HADS HADS 
PHQ n/a PHQ PHQ PHQ 
Subjective effects 
NRS (1without 
reinforcing drug 
effects) 
n/a Subjective effects 
NRS (2with 
reinforcing drug 
effects) 
Subjective effects 
NRS (with 
reinforcing drug 
effects) 
Depression NRS 
only 
 n/a - AUDIT - 
1 This was a partial battery measuring i) Bodily Symptoms (dizziness, drowsiness, nausea), ii) Cognitive/Mood 
Symptoms (mental confusion, depression), iii) Perceptual Symptoms (visual distortions, out of body experience) 
only. 2 This was the full subjective effects battery including all reinforcing drug effects questions (liking the drug, 
disliking the drug, feeling high, feeling a drug effect, wanting more of the drug) 
 
2.7 Statistical Analyses 
Statistical Package for Social Sciences (SPSS Version 25) was used to 
perform all analyses. Group differences for categorical variables (gender and 
educational levels) were examined with chi-square tests, and t-tests were used for the 
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continuous variable of age. Mann-Whitney U tests were used to compare the groups 
on AUDIT scores as this variable violated the assumption of normality. 
Distribution of data was assessed using, skewness and kurtosis data, 
histograms, p-p plots and the Kolmogorov–Smirnov test. Where these tests indicated 
that the assumptions of normality had been violated the decision was made to 
continue carrying out mixed ANOVAs. The rationale for this was based on Field 
(2013) where he noted that in samples of 40 or more with no outliers, the sampling 
distribution is usually normal according to central limit theorem. Furthermore, it is 
preferable to use a robust measure, such as an F-test, where possible.  After 
performing ANOVAs, the distribution of the residuals was examined. Where a 
violation of the assumption of normality was indicated, a secondary non-parametric 
analysis, using Mann-Whitney U tests of change scores was conducted to confirm 
findings. Secondary Mann-Whitney U tests are reported in appendix 9. 
The primary analysis aimed to examine the difference between the ketamine 
and lidocaine groups on measures of pain and mood over two timeframes: acutely 
(baseline, mid-infusion and post-infusion) and longer-term (baseline and one-week 
follow-up). 2(group: ketamine; lidocaine) x 3 (Time: baseline, mid-infusion and 
post-infusion) mixed ANOVAs were undertaken for the acute scores and 2 (group: 
Ketamine; Lidocaine) x 2 (baseline and one-week follow-up) mixed ANOVAs were 
undertaken for the follow-up scores. 
For the analysis exploring the subjective effects, 2(group: ketamine; 
lidocaine) x 3 (Time: baseline, mid-infusion and post-infusion) mixed ANOVAs 
were carried out. Where data was only collected at mid-infusion and post-infusion, 2 
(group: Ketamine; Lidocaine) x 2 (mid-infusion and post-infusion) mixed ANOVAs 
were carried out. 
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Assumptions of sphericity were assessed using Mauchley’s test and where 
this assumption was violated the Greenhouse-Geisser correction was applied. 
Homogeneity of variance was assessed using Levene’s test, and p values associated 
with post-hoc tests were Bonferroni corrected.  
To investigate the categorical HADS depression and anxiety clinical 
significance data (significant, not significant), the Fisher Exact test was used as data 
violated the assumptions of a chi-square test. Correlations were performed 
comparing change scores between baseline and follow-up for pain data (intensity, 
distress, interference) and mood measures (HADS Depression, HADS Anxiety, 
PHQ-2, Depression NRS). Since this data violated assumptions of normality, a 
Spearman's Rho correlation was conducted. 
 
3. Results  
3.1 Demographics (table 2) and Reported Alcohol Use (table 3) 
There were 58 participants in total: 24 ketamine patients (17 female, 7 male) 
and 34 lidocaine patients (27 female, 7 male). There were no statistically significant 
group differences in gender (χ2(1) =0.565, p=0.328) or age (t(56)=1.032, p=0.307). 
The sample was predominantly female (ketamine=70% female, lidocaine=79% 
female). However, when compared with the population of patients receiving 
treatment at the study site over the course of the study (72% female) there were no 
differences in the number of males and females in the two populations (χ2(2) = 
0.817, p = 0.665).  
The highest level of educational attainment by ketamine and lidocaine 
participants respectively were: GCSEs or equivalent (9/14), A-Levels or equivalent 
(4/3), Undergraduate degree or equivalent (5/11), Post-graduate degree or equivalent 
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(4/4). There were no statistically significant group differences in educational 
attainment (χ2 (3) = 1.686, p = 0.640). 
Participants in both treatment groups reported low levels of alcohol use. 
AUDIT total scores in the ketamine treatment group did not differ significantly from 
the lidocaine treatment group (U=259.500, z=-1.34, p=0.179). The majority of 
participants’ scores fell in the low-risk range for the AUDIT total score (33 
lidocaine, 20 Ketamine). The remaining participants scored in the ‘increasing risk’ 
range (2 lidocaine, 1 ketamine). No patients scored in the higher risk or possible 
dependence categories. The frequency of alcohol use in the ketamine treatment group 
did not differ significantly from the lidocaine treatment group (U=256.500, z=-1.43, 
p=0.154). Typical units of alcohol used in the ketamine treatment group did not 
differ significantly from the lidocaine treatment group (U=312.500, z=-0.38, 
p=0.702). The frequency of drinking more than six units of alcohol in the past year 
in the ketamine treatment group did not differ significantly from the lidocaine 
treatment group (U=258.500, z=-1.54, p=0.124). 
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Table 2 Summary of Group Demographics and AUDIT scores 
   Ketamine  Lidocaine 
Age 
 N Mean (sd) N Mean (sd) 
  
1Study Population 24 51.75 (13.19) 34 48.03 (13.76) 
 
2Full Population 74 55.77 (12.18) 188 50.20 (14.14) 
Gender 
(Female) 
 N (%)   N (%)   
  Study Population 18 (70.8%) 27 (79.4%) 
 Full Population 46 (62.2%) 137 (72.9) 
AUDIT Total 
Score 
 N Mean (sd) N Mean (sd) 
  Study Population 22 2.09 (3.13) 30 2.47 (2.24) 
Treatment 
Dose mg 
 
 N Mean (sd)  N Mean (sd) 
  Study Population  24 20.52 (12.59)  34 195.80 (61.68) 
1Study Population: All participants who participated in the full study, 2 Full Population: all patients attending the 
study site for infusions between February and May 2018. The study population data is included in the full 
population statistics. 
 
 
Table 3 Summary of participants’ alcohol use as AUDIT response frequencies 
    Never 
Monthly or 
Less 
2-4 times 
p/m 2-3 times p/w 
4+ 
times 
p/w 
How often do you have a 
drink containing alcohol? Ketamine  11 5 3  - 3 
  Lidocaine 8 10 4 6 2 
    0-2 3-4 5-6 7-9 10+ 
How many units of alcohol do 
you drink on a typical day 
when you are drinking? Ketamine  15 5 - 1 1 
  Lidocaine 18 11 1 - - 
    Never 
Less Than 
Monthly Monthly Weekly 
Daily 
or 
Almost 
Daily 
How often have you had 6 or 
more units* in the last year? Ketamine  17 2 1 - 1 
  Lidocaine 15 13 1 1 - 
  
Low 
Risk 
Increasing 
Risk 
Higher 
Risk 
Possible 
Dependency  
AUDIT Total Score Ketamine  33 1 - - - 
  Lidocaine 20 2 - - - 
 
 
 
 
3.2 Pain – Acute Effects 
3.2.1 Pain Intensity (Figure 1) 
A 2X3 mixed ANOVA, comparing baseline, mid-infusion and post-infusion 
scores, showed a significant interaction between drug group and time (F(1.89, 100) = 
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9.14, p<0.001) and a main effect of time (F(1.89, 100) = 64.57, p<0.001). No 
significant main effect of drug group was found (F(1, 50) = 3.02, p=0.088). Post hoc 
tests showed that the ketamine group scored significantly lower on pain intensity 
scores than the lidocaine group at mid-infusion (p=0.005, d= 0.82) and at the post-
infusion time points (p=0.030, d= 0.63). Significant reductions in pain intensity 
scores were found between baseline and mid-infusion for the ketamine (p<0.001, 
d=1.81) and lidocaine (p<0.001, d=0.79) groups, as well between baseline and post-
infusion for the ketamine (p<0.001, d=1.81) and lidocaine (p<0.001, d=1.03) groups. 
 
Figure 1 Group means for pain intensity scores of ketamine and lidocaine patients at each study time point. Bars 
represent standard errors. 
 
Bonferroni corrected post hoc tests comparing between group differences at acute time points (baseline, mid-
infusion, post-infusion). *= p <0.05, **= p< 0.01, ***= p < 0.001 
 
3.2.2 Pain Distress (table 4) 
A 2X3 mixed ANOVA, showed no significant interaction between drug 
group and time (F(2, 100) = 1.42, p=0.248), but a significant a main effect of time 
(F(2, 100) = 62.36, p<0.001) which reflected a reduction in pain distress scores from 
baseline to mid-infusion to post-infusion. No significant main effect of drug group 
was found (F(1, 50) = 0.40, p=0.529). 
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Table 4 Group means (sd) for pain NRS data. 
    Ketamine Lidocaine 
Pain Distress Baseline 6.09 (2.89) 5.97 (2.51) 
 Mid-Infusion 2.41 (2.58) 3.45 (2.56) 
 Post-Infusion 2.17 (2.10) 2.31 (2.16) 
  Follow-Up 4.83 (2.99) 4.00 (2.95) 
Pain Interference  Baseline 7.35 (2.48) 6.13 (3.17) 
  Follow-Up 7.21 (2.69) 5.45 (3.09) 
 
3.3 Pain - Baseline and One-week follow-up 
3.3.1 Pain Intensity (figure 1) 
A 2X2 mixed ANOVA, looking at baseline and one-week follow-up scores, 
showed no significant interaction between drug group and time (F(1, 53) = 0.62, 
p<0.433) but a significant main effect of time (F(1, 53) = 20.27, p<0.001) reflecting 
a reduction in pain intensity scores from baseline to the one-week follow-up. No 
significant main effect of drug group was found (F(1, 53) = 1.59, p=0.213). 
 
3.3.2 Pain Distress (table 4) 
A 2X2 mixed ANOVA showed no significant interaction between drug group 
and time (F(1, 53) = 1.46, p=0.232). A significant main effect of time (F(1, 53) = 
71.62, p<0.001) showed a reduction in pain distress scores from baseline to the one-
week follow-up. No significant main effect of drug group was found (F(1, 53) = 
0.25, p=0.617). 
 
3.3.3 Pain Interference (table 4) 
A 2X2 mixed ANOVA showed no significant interaction between drug group 
and time (F(1, 52) = 0.74, p=0.394). A significant main effect of time (F(1, 52) = 
12.14, p<0.001) showed a reduction in pain interference scores from baseline to the 
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one-week follow-up. No significant main effect of drug group was found (F(1, 52) = 
0.21, p=0.649). 
3.4 Mood  
3.4.1 PHQ-2 (table 5) 
A 2X2 mixed ANOVA, looking at baseline and 1-week follow-up scores, 
showed no significant interaction between drug group and time (F(1, 51) = 2.01, 
p=0.162). A significant main effect of time (F(1, 51) = 5.85, p=0.019) showed a 
reduction in PHQ-2 depression scores from baseline to the one-week follow-up. No 
significant main effect of drug group was found (F(1, 51) = 0.09, p=0.765). 
 
3.4.2 HADS Depression (table 5) 
A 2X2 mixed ANOVA, looking at baseline and 1-week follow-up scores, 
showed no significant interaction between time and drug group (F(1, 50) = 0.01, 
p=0.953). No significant main effect of time (F(1, 50) = 1.87, p=0.178) or drug 
group (F(1, 50) = 0.001, p=0.971) was found. 
 
3.4.3 HADS Anxiety (table 5) 
A 2X2 mixed ANOVA, looking at baseline and 1-week follow-up scores, 
showed no significant interaction between time and drug group (F(1, 51) = 2.87, 
p=0.096). A significant main effect of time (F(1, 51) = 53.58, p=0.005) showed a 
reduction in HADS anxiety scores from baseline to one-week follow-up. No 
significant main effect of drug group was found (F(1, 51) = 0.16, p=0.689  
 
Table 5 Group means (sd) for depression and anxiety measures. 
    Ketamine Lidocaine 
PHQ-2 Baseline 3.05 (2.14) 3.19 (2.26) 
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  Follow-up 2.82 (2.46) 2.32 (2.02) 
HADS Anxiety Baseline 9.59 (5.54) 9.29 (4.29) 
  Follow-up 7.32 (5.15) 8.68 (5.28) 
HADS Depression Baseline 9.41 (5.06) 9.33 (4.18) 
  Follow-up 8.68 (4.98) 8.67 (4.83) 
 
3.4.4 HADS Clinical Significance Data (table 6) 
Fisher Exact tests were conducted on the population of patients who scored in 
the clinically significant range for HADS depression at baseline. The tests revealed 
that there were no significant differences in numbers of ketamine and lidocaine 
patients scoring in the clinically significant range and non-clinically significant range 
at the 1-week follow up (p=0.159).  
Fisher Exact tests were also conducted on the patients who scored in the 
clinically significant range for HADS anxiety at baseline. The tests showed that there 
were no significant differences in the distribution of clinically significant and non-
clinically significant scoring patients at the 1-week follow up (p=0.697).  
 
Table 6 Group frequencies at one-week follow-up for clinical significance data 
    Ketamine  Lidocaine 
Anxiety Normal 3 2 
 Borderline 2 3 
  
Clinically 
Significant 6 9 
Depression Normal 0 2 
 Borderline 1 4 
  
Clinically 
Significant 8 6 
 
3.4.5 Depression NRS (figure 2) 
Acute: A 2X3 mixed ANOVA, looking at baseline, mid-infusion, post-
infusion scores, showed a significant interaction between drug group and time (F(2, 
98) = 4.01, p=0.021) and a main effect of time (F(2, 98) = 47.58, p<0.001). No 
significant main effect of drug group was found (F(1, 49) = 0.89, p=0.351).  To 
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explore the interaction, Bonferroni corrected post-hoc tests were used and revealed 
that the ketamine group had significantly higher depression ratings at baseline than 
the lidocaine group (p=0.041, d= 0.60). Significant reductions in depression scores 
were found between baseline and mid-infusion for the ketamine (p<0.001, d=1.39) 
and lidocaine (p<0.001, d=0.81) groups, as well between baseline and post-infusion 
for the ketamine (p<0.001, d=0.98) and lidocaine (p<0.001, d=0.96) groups. 
Baseline and One-week follow-up: A 2X2 mixed ANOVA, looking at 
baseline and 1-week follow-up scores, showed that there was a no significant 
interaction between drug group and time (F(1, 52) = 0.44, p=0.512) and a significant 
effect of time (F(1, 52) = 21.16, p<0.001) reflecting a reduction in depression NRS 
scores from baseline to the one-week follow-up. No significant main effect of drug 
group was found (F(1, 52) = 1.90, p=0.174). 
 
Figure 2 Group Means for depression NRS scores of ketamine and lidocaine patients at each study time point. 
Bars represent standard errors. 
 
Bonferroni corrected post hoc tests comparing between group differences at acute time points (baseline, mid-
infusion, post-infusion). *= p <0.05, **= p< 0.01, ***= p < 0.001 
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3.5 Drug Effects (table 7)  
 
Table 7 Group means (sd) for the drug effects NRS and post-hoc significance data comparing between-group 
differences at each study time point (baseline, mid-infusion, post-infusion) 
    Ketamine  Lidocaine Significance 
Dizziness Baseline 3.67 (3.10) 3.18 (3.36)   
 Mid-Infusion 5.87 (3.11) 2.36 (3.17) b** 
  Post-Infusion 3.04 (2.35) 2.13 (2.47)   
Drowsiness Baseline 4.29 (3.14) 3.65 (3.30)   
 Mid-Infusion 6.52 (3.06) 4.55 (3.24) b*  
  Post-Infusion 3.61 (2.71) 3.87 (3.37)   
Depression  Baseline 5.83 (3.32) 4.53 (3.01) a* 
 Mid-Infusion 1.71 (2.56) 2.24 (2.59)  
 Post-Infusion 2.52 (3.41) 1.83 (2.35)  
  Follow-up 3.88 (3.26) 3.03 (3.22)   
Nausea Baseline 2.67 (2.63) 1.88 (2.98)   
 Mid-Infusion 1.61 (2.04) 1.64 (2.87)  
  Post-Infusion 0.96 (1.36) 1.97 (2.95)   
Visual Distortions Baseline 3.13 (3.49) 2.09 (2.95)   
 Mid-Infusion 3.23 (2.69) 1.58 (2.57) b* 
  Post-Infusion 1.7 (2.06) 1.1 (1.69)   
	 94	
Out of Body 
Feeling Baseline 1.58 (2.93) 1.24 (2.56)   
 Mid-Infusion 1.78 (2.94) 0.76 (1.94)  
  Post-Infusion 1.09 (2.13) 0.97 (2.21)   
Mental Confusion Baseline 2.58 (3.23) 2.12 (3.10)   
 Mid-Infusion 3.13 (3.24) 1.18 (2.29)  
  Post-Infusion 1.91 (2.39) 0.9 (1.58)   
Feel Drug Effect Mid-Infusion 6.96 (3.08) 3.70 (2.91) b*** 
  Post-Infusion 3.74 (1.98) 2.83 (2.96)   
High Mid-Infusion 6.13 (3.01) 1.3 (2.01) b*** 
  Post-Infusion 2.48 (1.73) 1.2 (2.11) c*** 
Dislike Drug 
Effect Mid-Infusion 1.74 (2.32) 0.58 (1.25)   
  Post-Infusion 1.78 (2.63) 0.83 (2.23)   
Liking Drug Mid-Infusion 4.78 (2.97) 2.94 (3.29)   
  Post-Infusion 4.39 (3.13) 2.97 (3.19)   
Wanting More 
Drug Mid-Infusion 2.65 (3.37) 2.00 (3.22)  
  Post-Infusion 2.00 (3.05) 2.14 (3.27)   
Bonferroni corrected post hoc tests comparing between group differences at acute time points (baseline, mid-
infusion, post-infusion). *= p <0.05, **= p< 0.01, ***= p < 0.001 
a = baseline b =mid-infusion c= post-infusion 
 
3.5.1 Dizziness (figure 3) 
A 2X3 mixed ANOVA, showed a significant interaction between drug group 
and time (F(2, 100) = 5.30, p=0.006) and a main effect of time (F(2, 100) = 6.38, 
p=0.002). No significant main effect of drug group was found (F(1, 50) = 0.01, 
p=0.947). Bonferroni corrected post-hoc tests revealed that the ketamine group felt 
significantly dizzier than the lidocaine group at mid-infusion (p= 0.005, d= 0.82). In 
addition, the ketamine group showed a significant increase in ratings of dizziness 
from baseline to mid-infusion (p= 0.005, d= 0.71). 
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Figure 3 Group means for dizziness scores of ketamine and lidocaine patients at each study time point. Bars 
represent standard errors. 
 
Bonferroni corrected post hoc tests comparing between group differences at acute time points (baseline, mid-
infusion, post-infusion). *= p <0.05, **= p< 0.01, ***= p < 0.001 
 
3.5.2 Drowsiness (figure 4) 
A 2X3 mixed ANOVA showed that there was a trend towards a significant 
interaction between drug group and time (F(2, 98) = 2.81, p=0.065) and a significant 
main effect of time (F(2, 98) = 9.11, p<0.001). No significant main effect of drug 
group was found (F(1, 49) = 1.94, p=0.170). To explore the trend towards an 
interaction Bonferroni corrected post-hoc tests were carried out. Tests revealed that 
the ketamine group felt significantly drowsier than the lidocaine group at mid-
infusion (p=0.03, d=0.64) and that the ketamine group showed a significant increase 
in ratings of drowsiness from baseline to mid-infusion (p=0.045, d=0.84).  
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Figure 4 Group means for drowsiness scores of ketamine and lidocaine patients at each study time point. Bars 
represent standard errors. 
 
Bonferroni corrected post hoc tests comparing between group differences at acute time points (baseline, mid-
infusion, post-infusion). *= p <0.05, **= p< 0.01, ***= p < 0.001 
 
 
3.5.4 Nausea (figure 5) 
A 2X3 mixed ANOVA showed a significant interaction between drug group 
and time (F(2, 98) = 4.60, p=0.012 and a significant main effect of time (F(2, 98) = 
3.24, p=0.40). No significant main effect of drug group was found (F(1, 49) = 0.01, 
p=0.952).  Bonferroni corrected post-hoc tests revealed that the ketamine group had a 
significant reduction in ratings of nausea from baseline to post-infusion (p=0.005, 
d=0.72). 
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Figure 5 Group means for nausea scores of ketamine and lidocaine patients at each study time point. Bars 
represent standard errors. 
 
Bonferroni corrected post hoc tests comparing between group differences at acute time points (baseline, mid-
infusion, post-infusion). *= p <0.05, **= p< 0.01, ***= p < 0.001 
 
3.5.6 Visual Distortion (figure 6) 
A 2X3 mixed ANOVA, showed a significant interaction between drug group 
and time (F(2, 98) = 5.94, p=0.004) and a significant main effect of time (F(2, 98) = 
11.37, p<0.001). No significant main effect of drug group was found (F(1, 49) = 
1.22, p=0.275).  Bonferroni corrected post-hoc tests revealed that the ketamine group 
experienced significantly more visual distortions at the mid-infusion time point 
(p=0.025, d=0.66) and significantly more visual distortions at the post-infusion time 
point (p=0.040, d=0.60) than the lidocaine group. 
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Figure 6 Group means for visual distortion scores of ketamine and lidocaine patients at each study time point. 
Bars represent standard errors. 
 
Bonferroni corrected post hoc tests comparing between group differences at acute time points (baseline, mid-
infusion, post-infusion). *= p <0.05, **= p< 0.01, ***= p < 0.001 
 
3.5.6 Out of Body Experience 
A 2X3 mixed ANOVA showed no significant interaction between drug group 
and time (F(2, 98) = 0.71, p=0.470 and no significant main effect of time (F(2, 98) = 
0.76, p=0.470) or drug group (F(1, 49) = 1.56, p=0.218). 
 
3.5.7 Mental Confusion 
A 2X3 mixed ANOVA showed no significant interaction between drug group 
and time (F(1.74, 3.67) = 1.64, p=0.203). There was a significant main effect of time 
(F(1.74, 3.67) = 3.86, p=0.030) and drug group (F(1, 49) = 5.73, p=0.021). The main 
effect of time reflected a slight decrease in mean mental confusion scores post-
infusion. The main effect of drug group reflected higher ratings of mental confusion 
in the ketamine group. 
 
0
1
2
3
4
5
6
7
8
9
10
Baseline Mid-Infusion Post	Infusion
M
ea
n	
Vi
su
al
	D
ist
or
io
n	
Sc
or
e
Time	Point
Ketamine
Lidocaine
**
	 99	
3.5.8 Feeling an effect of the drug (figure 7) 
A 2X2 mixed ANOVA, looking at mid-infusion and post-infusion scores, 
showed a significant interaction between drug group and time (F(1, 49) = 8.65, 
p=0.005). There was a significant main effect of time (F(1, 49) = 29.06, p<0.001) 
and drug group (F(1, 49) = 13.84, p=0.001).  Bonferroni corrected post-hoc tests 
showed that the ketamine group experienced a significantly greater feeling of a drug 
effect at the mid-infusion time point (p<0.001, d= 1.29) than the lidocaine group.  
Significant reductions in feeling a drug effect from mid-infusion to post-infusion 
were found for both the ketamine (p<0.001, d=1.24) and lidocaine (p<0.001, d=0.30) 
groups. 
Figure 7 Group means for feeling a drug effect scores of ketamine and lidocaine patients at each study time 
point. Bars represent standard errors. 
 
Bonferroni corrected post hoc tests comparing between group differences at acute time points (baseline, mid-
infusion, post-infusion). *= p <0.05, **= p< 0.01, ***= p < 0.001 
 
3.5.9 Feeling High (figure 8) 
A 2X2 mixed ANOVA showed a significant interaction between drug group 
and time (F(1, 49) = 20.95, p<0.001). A significant main effect of time (F(1, 49) = 
37.06, p<0.001) and drug group (F(1, 49) = 35.64, p<0.001) was found. Bonferroni 
corrected post-hoc tests revealed that the ketamine group experienced a significantly 
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greater feeling of being high than the lidocaine group, at the mid-infusion time point 
(p<0.001, d=1.82) and the post-infusion time point (p=0.001, d= 0.97). The ketamine 
group also showed a significant reduction in feeling high from mid-infusion to post-
infusion (p<0.001, d=1.25). 
Figure 8 Group means for feeling high drug effect scores of ketamine and lidocaine patients at each study time 
point. Bars represent standard errors. 
 
Bonferroni corrected post hoc tests comparing between group differences at acute time points (baseline, mid-
infusion, post-infusion). *= p <0.05, **= p< 0.01, ***= p < 0.001 
 
3.5.10 Disliking the Drug Effects 
A 2X2 mixed ANOVA, showed no significant interaction between drug 
group and time (F(1, 49) = 0.91, p=0.345). no significant main effect of time (F(1, 
49) = 0.07, p=0.795) or drug group (F(1, 49) = 3.45, p=0.069) were found.  
 
3.5.11 Subjective Ratings of Liking the Drug 
A 2X2 mixed ANOVA showed that there was no significant interaction 
between drug group and time (F,(1.69, 71.28) = 0.84 p=0.418).  There was no 
significant main effect of time (F(1.69, 71.28) = 0.28, p=0.435) but a significant 
main effect of drug group was found (F(1, 48) = 5.59, p=0.023) reflecting higher 
ratings of liking the drug effect in the ketamine group.  
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3.5.12 Wanting More of the Drug  
A 2X2 mixed ANOVA showed that there was no significant interaction 
between drug group and time (F(1, 48) = 2.26, p=0.140) and no significant main 
effect of time (F(1, 48) = 1.48, p=0.229) or drug group (F(1, 48) = 0.53, p=0.088) 
was found 
 
3.6 Correlations - Pain and Depression Measures 
3.6.1 Lidocaine group (Figure 9) 
No significant correlations were found between change scores (baseline and 
1-week follow-up) in pain intensity or pain interference and change scores in mood 
measures (HADS, PHQ-2, depression NRS).  A significant correlation was found 
between pain distress and depression NRS change scores (rs =0.400, p=0.043).  
 
Figure 9 Lidocaine group: Correlation between Pain Intensity and Depression NRS Change Scores, (n=31) 
 
 
3.6.2 Ketamine group (Figure 10) 
A significant correlation was found between pain intensity change scores and 
HADS anxiety change scores (rs =0.447, p=0.037) and pain interference and HADS 
anxiety change scores (rs =0.467, p=0.029). A significant correlation was also found 
-10
-8
-6
-4
-2
0
2
4
6
8
10
-10 -5 0 5 10
De
pr
es
sio
n	
NR
S	C
ha
ng
e	
Sc
or
es
Pain	Intensity	Change	Scores
	 102	
between pain intensity change scores and the depression NRS change scores (rs 
=0.509, p=0.016).   
Figure 10a. Ketamine group: Correlation between Pain Intensity and HADS Anxiety Change Scores, (n=24) 
 
 
Figure 10b. Ketamine group: Correlation between Pain Interference and HADS Anxiety Change Scores, (n=24) 
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Figure 10c. Ketamine group: Correlation between Pain Intensity and Depression NRS Change Scores, (n=24) 
 
 
 
4. Discussion 
This study compared the effects of ketamine and lidocaine, in chronic pain 
patients on pain, mood and subjective drug effects. Both ketamine and lidocaine 
produced significant reductions in ratings of pain intensity and distress at the acute 
phase (baseline, mid-infusion and post-infusion). At the one-week follow-up, all 
three pain ratings (intensity, distress and interference) were significantly reduced 
relative to baseline. No group differences were seen at the follow-up. However, 
ketamine reduced pain intensity at the acute phase of treatment (mid-infusion and 
post-infusion) more than lidocaine. 
Data from the mood measures presented a mixed picture. PHQ-2 and 
depression NRS data showed a significant reduction in scores at the one-week 
follow-up for both drug groups. However, HADS depression data did not show any 
significant changes, for either drug group, at any time-point. HADS anxiety scores 
were reduced from baseline to one-week follow-up in both drug groups. Depression 
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NRS ratings were acutely reduced in both ketamine and lidocaine (baseline, mid-
infusion, post-infusion) but were higher in the ketamine group at baseline.  
Regarding subjective drug effects, during the infusion, the ketamine group 
felt significantly more ‘high’, felt a greater sensation of a drug effect, liked the drug 
effect more, and felt more mentally confused than the lidocaine group. Additionally, 
the ketamine group experienced higher levels of visual distortions, dizziness, and 
drowsiness than the lidocaine group. This is in line with the known psychedelic and 
sedative effects of ketamine (Aan Het Rot et al., 2012, Blier et al., 2012).  
 
4.1 Pain 
Both drugs significantly reduced participants pain on all three indices 
measured (intensity, distress, interference). Ketamine produced a greater reduction in 
pain intensity, during the infusion, than lidocaine. However, at the one-week follow-
up, no group differences were found indicating a similar impact in reducing 
participants pain between the two treatments at this time point.  Indeed, a large 
number of studies have shown that ketamine is associated with significant pain relief 
during infusions (Hocking & Cousins, 2003; Nourozi et al. 2010; Finch et al., 2009). 
Given the design of our study, we were unable to investigate how long these effects 
were sustained for after the one-week follow-up. However, it appeared that the 
greater level of pain relief, reported at mid-infusion and post-infusion time-points, in 
the ketamine group was not sustained at the one-week follow-up. A meta-analysis by 
Niesters et al., (2013) suggested that to induce sustained analgesia, in patients with 
complex regional pain syndrome, a high frequency of infusions is needed (e.g. 
several infusions over 4-14 days). In the current study, patients were given infusions 
of ketamine for between 30 minutes to one hour in frequencies of every two-to-three 
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months. As such, further study will be needed to establish standards for routine 
treatment regimes. 
Reductions in pain intensity reported at the one-week follow-up, for both 
drugs, was modest (ketamine mean pain intensity change score = -1.31; lidocaine 
mean pain intensity change score = -1.67). Thus, for both drugs, the pain relief 
benefits were small at the one-week time-point. However, during the one-week 
follow-up phone call seven ketamine participants and nine lidocaine participants 
stated that while they had not yet fully experienced the benefit of their infusion, 
based on previous experience with these treatments, they expected to experience a 
continued reduction in pain over the next one-to-two weeks. Thus, the study’s one-
week follow-up period may have been too short to assess the full benefits that the 
participants expected to gain from the treatment.  
 
4.2 Depression 
The results from this study show a mixed picture with regards to the effects 
of ketamine treatment on mood. Improvements in scores of depressed mood were 
found across both drug groups when looking at PHQ-2 and depression NRS data. 
However, this effect was not found when looking at the HADS depression data.  
Additionally, correlation analyses indicated that, for both ketamine and lidocaine 
patients, reductions in pain intensity scores were associated with reductions in 
depression NRS. Interestingly these correlations were not present for either the PHQ-
2 scores or the HADS depression scores.  
The lack of consistency in findings on measures of depression in the current 
study may further highlight the challenges of assessing mood in this population. Both 
the PHQ-2 and depression NRS ask broad questions regarding depressed mood. 
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However, the HADS depression scale was developed with the purpose of being used 
in a physical health setting. Indeed, a major methodological challenge in studying 
depression, in chronic pain populations, is measure choice. The HADS was chosen 
as the most suitable measure, and the PHQ-2 and depression NRS was chosen to 
provide generalizability of results to studies investigating the antidepressant and 
reinforcing properties of ketamine. One possible explanation for the discrepancy in 
the results may be that the PHQ-2 and Depression NRS lack specificity when used 
with this population. That is, given the small number of items, which broadly ask 
about depressed mood, alongside the presence of chronic pain, increases or 
reductions in scores may be inflated. Thus, results from the PHQ-2 and Depression 
NRS may also be measuring changes that are linked with changes in pain 
presentation. As such, scores from these measures should be interpreted with caution. 
Given that ketamine has potent anti-depressant properties in depressed 
individuals, we aimed to explore ketamine’s effects on mood in chronic pain 
patients. Secondary analysis, looking specifically at the group of participants who 
scored in the clinically significant range for depression on the HADS, indicated no 
significant differences between either drug group at the one-week follow-up. 
Interestingly, group frequencies showed that six out of the 12 lidocaine participants 
who scored in the clinically significant range at baseline, either fell in the borderline 
range (N=4) or normal range (N=2) at one-week follow-up. Conversely, out of the 
nine ketamine patients who scored in the clinically significant range only one moved 
to the borderline range at the one-week follow-up. Thus, a tentative interpretation of 
this may be that the ketamine group had less of a response, with regards to 
improvement in mood, than the lidocaine group, and statistical analyses lacked the 
power to confirm this.  One explanation for this may be that the frequency and 
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duration of ketamine treatment received at the study site were not high enough to 
show an impact on participant's mood.  
Research has shown that in the treatment of refractory depression, with 
ketamine, infusions three times a week over the course of 14-days have a median 
time of relapse of 18-days among the group of participants who responded to the 
treatment (Murrough et al., 2013). Thus, ketamine treatment for pain, depression or 
both co-morbidly may require maintenance dosing to maintain a response to the 
drug. However, given the lack of standardized protocol in treating pain and/or mood 
disorders with ketamine, further study will be necessary to establish treatment 
regimes.  
Overall, these findings do not indicate that ketamine has specific 
antidepressant effects in a chronic pain setting. Tentative interpretation of results 
indicates that improvements in mood were observed in both ketamine and lidocaine 
groups. Thus, general improvements in quality of life (i.e. greater participation in 
social activities), as a result of pain relief, may have led to the improvements in 
depressed mood.  
Additionally, the majority of participants in our study did not meet the 
criteria at baseline for clinically significant depression (HADS depression scores) so 
are very different from those with treatment-resistant depression who respond to the 
antidepressant effects of ketamine. Thus, one would not expect to see an effect in 
those who do not present as depressed at baseline. 
 
4.3 Anxiety 
There was a significant decrease in HADS anxiety scores from baseline to 
one-week follow-up for both drug groups. Correlation analyses indicated an 
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association between a reduction in both pain intensity and interference scores 
(baseline and one-week follow-up) with a reduction in HADS anxiety scores for the 
ketamine group. Indeed, several clinical studies have suggested that ketamine may 
have significant anxiolytic effects (Salvador et al., 2009; Zarate et al., 2006; Taylor 
et al., 2018). Thus, very tentatively, a possible direction for future research may be to 
explore the effects of ketamine on anxiety in the chronic pain population. 
 
4.4 Subjective Drug Effects 
Analysis indicated that the ketamine and lidocaine groups showed different 
ratings on some of the subjective drug effects NRS. The ketamine group felt 
significantly drowsier and dizzier than the lidocaine group at mid-infusion and had 
higher overall ratings of mental confusion. All measures returned to baseline levels 
at the post-infusion time-point indicating the short-lived nature of these side effects. 
With regard to perceptual symptoms, the ketamine group experienced 
significantly stronger visual distortions at the mid-infusion time-point than the 
lidocaine group. This is in line with the expected side effect profile of ketamine (Aan 
Het Rot et al., 2012, Blier et al., 2012). However, mid-infusion means (ketamine 
M=3.23, SD= 2.69) indicate that these effects were mild which may reflect the 
relatively low doses administered at the study site.  
The ketamine group experienced a much stronger ‘drug effect’ and felt more 
‘high’ than the lidocaine group. In addition to this, the ketamine group on average 
liked the effects of the treatment more than the lidocaine group.  Thus, given the 
acute reinforcing effects of ketamine in humans and animals, these effects were 
expected. Studies with healthy volunteers have also shown that ketamine increases 
subjective ratings of feeling ‘high’ (Krystal et al., 1999) and that these relate to its 
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abuse potential. However, in this study, participants average ratings of ‘wanting 
more drug' were low at both mid-infusion and post-infusion. These findings may 
suggest that the ketamine treatment group are unlikely to seek the drug outside of the 
pain clinic for its reinforcing effects. Thus, the treatment offered at the study site 
may have a low abuse potential and chronic pain patients may react differently to 
healthy volunteers administered ketamine in a controlled study (cf. Morgan et al., 
2004).  
 
4.5 Methodological Considerations 
Firstly, recruitment proved to be more challenging than expected. In 
particular, the population of patients being treated with the drug ketamine was 
smaller than initially anticipated. In addition to this, a high drop out rate was 
experienced throughout the study due to patients reporting that they were in too 
much pain to participate. Thus, we were unable to recruit the target number of 40 
participants per group. As a result, the statistical analyses may have been 
underpowered therefore increasing the chance of Type II error.  
The fact that a high proportion of the data violated assumptions of normality 
should be noted. Transformation of data did not better approximate normality. Where 
possible non-parametric tests were carried out. However, due to there being no non-
parametric equivalent of a mixed ANOVA it was decided that researchers would 
carry out mixed ANOVAs in conjunction with secondary Mann-Whitney U tests as a 
means of checking the effects observed in the ANOVAs. Thus, the increased risk of 
Type 1 error associated with the large number of statistical analyses undertaken 
needs to be considered as a limitation.  
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The one-week follow-up phone call was not conducted in the same 
environment as the acute phase of the study. In addition to this, all questions were 
asked verbally by researchers at the one-week follow-up, whereas during the acute 
phase of testing participants were able to read the questions as they were being 
asked. This may have affected how participants responded to the self-rating measures 
at this time-point.    
Perhaps the greatest methodological challenge in this study was measuring 
mood in the context of chronic pain. The HADS was chosen as the most practical 
measure for use in this population given its development for specific use in a 
physical health setting. However, given the HADS unstable factor structure (Coyne 
and van Sonderen 2012; Cosco et al. 2012) it remains problematic for use in 
research. Further to this, we used two further measures of mood (PHQ-2; depression 
NRS). These measures were chosen because of their past use in studies of the 
antidepressant and reinforcing effects of ketamine and their brevity. Having 
measures that could be completed quickly was important so the research would have 
minimal impact on the clinical team at the study site. However, given the lack of 
consistency in findings between the mood measures, these results need to be 
interpreted with caution.  Indeed, further studies to validate the use of these 
measures, in this population is warranted. Further to this, these findings highlight the 
complexity and challenges of making accurate diagnoses of depression in this 
population.  
Finally, the population of patients accessed at the study site varied 
considerably regarding age range, diagnoses, current medications and day-to-day 
functioning. Thus, there were many external factors which may have influenced the 
results which were difficult to control for.  
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4.6 Directions for Future Research 
Future research should aim to conduct a similar study with a more 
comprehensive follow-up regime. This would allow researchers to gain a greater 
understanding of how long the effects of the treatment last. Future research should 
continue to look at the possibility of the treatment of co-morbid mood disorder and 
chronic pain. However, the mood measurement paradigm should be expanded to 
include a more comprehensive study of this area. Indeed, the development of new 
measures which are suitable for the diagnosis of depression in the chronic pain 
population is essential. Currently, there is a dearth of research in this area, and it is 
important to continue to explore treatment options for this group of patients. In 
particular, to carry out studies with larger sample sizes and more power.  
 
4.7 Clinical Implications 
The present study has several clinical implications. Firstly, subjective effects 
showed that the ketamine group felt significantly more intense drug effects, feeling 
more high and liking the effects of the drug more than those who were treated with 
lidocaine. Given the abuse potential of ketamine, this needs to be taken into 
consideration when treating people with ketamine. However, both the ketamine and 
lidocaine groups scored on average very low on the NRS ‘wanting more of the drug' 
indicating that the population being studied was unlikely to seek the drug for use 
outside of the clinic.   
Secondly, the results of the study tentatively add to the evidence base for the 
efficacy of the drug ketamine in treating chronic pain. However, it is clear that 
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further comprehensive follow-up of the impact of the treatment is needed. In 
particular, how long effects are sustained for and how the dosing regime effects this. 
Finally, the impact of ketamine treatment on mood in this population remains 
unclear. Thus, it is important that this is evaluated in clinical practice. Use of 
depression measures should be treated with caution, and the need for research to 
develop new measures is warranted. 
 
4.8 Summary 
In summary, the findings described here provide an exploratory analysis of 
the use of ketamine in the treatment of chronic pain. The findings tentatively suggest 
ketamine treatment reduced symptoms of chronic pain. Additionally, the study adds 
to the evidence base in describing ketamine’s symptom profile and highlights how 
the patients in the study population responded to the drug. In particular, feeling high 
and liking the drug effects. Thus, providing important information for clinicians who 
are considering prescribing the drug. Finally, concerning ketamine's potential effects 
on mood in this population, the current study has highlighted the need for further 
research. In particular, for this research to include rigorous follow-up processes and 
careful choice of measures to evaluate treatment impact. 
 
 
 
 
 
 
	 113	
References 
 
Aan Het Rot, M., Zarate, C. A., Charney, D. S., & Mathew, S. J. (2012). Ketamine 
for depression: where do we go from here?. Biological Psychiatry, 72, 537-547. 
 
Abdallah, C. G., Averill, L. A., & Krystal, J. H. (2015). Ketamine as a promising 
prototype for a new generation of rapid-acting antidepressants. Annals of the New 
York Academy of Sciences, 1344, 66-77. 
 
Azari, P., Lindsay, D. R., Briones, D., Clarke, C., Buchheit, T., & Pyati, S. (2012). 
Efficacy and Safety of Ketamine in Patients with Complex Regional Pain 
Syndrome. CNS Drugs, 26, 215-228. 
 
Banks, S., & Kerns, R. (1996). Explaining high rates of depression in chronic pain: A 
diathesis-stress framework. Psychological Bulletin, 119, 95–110. 
 
Berman, R. M., Cappiello, A., Anand, A., Oren, D. A., Heninger, G. R., Charney, D. 
S., & Krystal, J. H. (2000). Antidepressant effects of ketamine in depressed 
patients. Biological Psychiatry, 47, 351-354. 
 
Bjelland, I., Dahl, A.A., Haug, T.T., Neckelmann, D. (2002). The validity of the 
Hospital Anxiety and Depression Scale an updated literature review. Journal of 
Psychosomatic Research, 52, 69-77. 
 
	 114	
Blier, P., Zigman, D., & Blier, J. (2012). On the safety and benefits of repeated 
intravenous injections of ketamine for depression. Biological Psychiatry, 72, 11-12. 
 
Blumer, D., & Heilbronn, M. (1982). Chronic pain as a variant of depressive disease: 
The pain-prone disorder. The Journal of Nervous and Mental Disease, 170, 381–406. 
 
Bobo, W. V., Vande Voort, J. L., Croarkin, P. E., Leung, J. G., Tye, S. J., & Frye, M. 
A. (2016). Ketamine for treatment-resistant unipolar and bipolar major depression: 
critical review and implications for clinical practice. Depression and Anxiety, 33, 
698-710. 
 
Bolton, J. E., & Wilkinson, R. C. (1998). Responsiveness of pain scales: a 
comparison of three pain intensity measures in chiropractic patients. Journal of 
Manipulative and Physiological Therapeutics, 21, 1-7. 
 
Bone, M., Critchley, P., & Buggy, D. J. (2002). Gabapentin in postamputation 
phantom limb pain: a randomized, double-blind, placebo-controlled, cross-over 
study. Regional Anesthesia and Pain Medicine, 27, 481-486. 
 
Breivik, E. K., Björnsson, G. A., & Skovlund, E. (2000). A comparison of pain 
rating scales by sampling from clinical trial data. The Clinical Journal of Pain, 16, 
22-28. 
 
Caddy, C., Giaroli, G., White, T. P., Shergill, S. S., & Tracy, D. K. (2014). Ketamine 
as the prototype glutamatergic antidepressant: pharmacodynamic actions, and a 
	 115	
systematic review and meta-analysis of efficacy. Therapeutic Advances in 
Psychopharmacology, 4, 75-99. 
 
Chanques, G., Viel, E., Constantin, J. M., Jung, B., de Lattre, S., Carr, J., ... & Jaber, 
S. (2010). The measurement of pain in intensive care unit: comparison of 5 self-
report intensity scales. Pain, 151, 711-721. 
 
Clements, J. A., Nimmo, W. S., & Grant, I. S. (1982). Bioavailability, 
pharmacokinetics, and analgesic activity of ketamine in humans. Journal of 
Pharmaceutical Sciences, 71, 539-542. 
 
Corrsen G, Reves JG, Stanley TH (1988): Dissociative anesthesia: In: Corrsen G, 
Reves JG, Stanley TH, editors. Intravenous Anesthesia and Analgesia. Philadelphia: 
Lea and Febiger, 99–173 
 
Cosco, T. D., Doyle, F., Ward, M., & McGee, H. (2012). Latent structure of the 
Hospital Anxiety and Depression scale: A 10-year systematic review. Journal of 
Psychosomatic Research, 72, 180–184.  
 
Coyle, C. M., & Laws, K. R. (2015). The use of ketamine as an antidepressant: a 
systematic review and meta-analysis. Human Psychopharmacology: Clinical and 
Experimental, 30, 152-163. 
 
Coyne, J., & van Sonderen, E. (2012). No further research needed: Abandoning the 
	 116	
Hospital Anxiety and Depression Scale (HADS). Journal of Psychosomatic 
Research, 72, 173–174.  
 
Dworkin, R. H., O'connor, A. B., Audette, J., Baron, R., Gourlay, G. K., Haanpää, 
M. L.,& Mackey, S. C. (2010, March). Recommendations for the pharmacological 
management of neuropathic pain: an overview and literature update. In Mayo Clinic 
Proceedings (Vol. 85, No. 3, pp. S3-S14). Elsevier. 
 
Faul, F., Erdfelder, E., Lang, A.-G., & Buchner, A. (2007). G*Power 3: A flexible 
statistical power analysis for the social, behavioral, and biomedical sciences. 
Behavior Research Methods, 39, 175-191  
 
Fayaz, A., Croft, P., Langford, R. M., Donaldson, L. J., & Jones, G. T. (2016). 
Prevalence of chronic pain in the UK: a systematic review and meta-analysis of 
population studies. BMJ open, 6, e010364. 
 
Field, A. (2013). Discovering statistics using IBM SPSS statistics. Sage 
 
Finch PM, Knudsen L, Drummond PD. (2009). Reduction of allodynia in patients 
with complex regional pain syndrome: a double-blind placebo-controlled trial of 
topical ketamine. Pain, 146, 18-25  
 
Finnerup, N. B., Otto, M., McQuay, H. J., Jensen, T. S., & Sindrup, S. H. (2005). 
	 117	
Algorithm for neuropathic pain treatment: an evidence based proposal. Pain, 118, 
289-305. 
 
Fond, G., Loundou, A., Rabu, C., Macgregor, A., Lançon, C., Brittner, M., ... & 
Roger, M. (2014). Ketamine administration in depressive disorders: a systematic 
review and meta-analysis. Psychopharmacology, 231(, 3663-3676. 
 
Harrison, Y. E., Jenkins, J. A., Rocha, B. A., Lytle, D. A., Jung, M. E., & Oglesby, 
M. W. (1998). Discriminative stimulus effects of diazepam, ketamine and their 
mixture: ethanol substitution patterns. Behavioural pharmacology, 9, 31-40. 
 
Hocking, G., & Cousins, M. J. (2003). Ketamine in chronic pain management: an 
evidence-based review. Anesthesia & Analgesia, 97, 1730-1739. 
 
Jensen, M. P., Karoly, P., & Braver, S. (1986). The measurement of clinical pain 
intensity: A comparison of six methods. Pain, 27, 117–126.  
 
Jensen, M. P., Karoly, P., O’Riordan, E. F., Bland, F., & Burns, R. S. (1989). The 
subjective experience of acute pain: An assessment of the utility of 10 indices. The 
Clinical Journal of Pain, 5, 153–159.  
 
Kessler, R. C., Berglund, P., Demler, O., Jin, R., Koretz, D., Merikangas, K. R., & 
Wang, P. S. (2003). The epidemiology of major depressive disorder: results from the 
National Comorbidity Survey Replication (NCS-R). Jama, 289, 3095-3105. 
 
	 118	
Kroenke, K., Spitzer, R. L., & Williams, J. B. (2003). The Patient Health 
Questionnaire-2: validity of a two-item depression screener. Medical care, 41, 1284-
1292. 
 
Krystal, J. H., D’Souza, D. C., Karper, L. P., Bennett, A., Abi-Dargham, A., Abi-
Saab, D., ... & Charney, D. S. (1999). Interactive effects of subanesthetic ketamine 
and haloperidol in healthy humans. Psychopharmacology, 145, 193-204. 
 
Krystal, J. H., Petrakis, I. L., Limoncelli, D., Nappi, S. K., Trevisan, L., Pittman, B., 
& D'souza, D. C. (2011). Characterization of the interactive effects of glycine and D-
cycloserine in men: further evidence for enhanced NMDA receptor function 
associated with human alcohol dependence. Neuropsychopharmacology, 36, 701. 
 
Krystal J. H., Petrakis I. L.,Webb E., CooneyN. L.,Karper L. P.,Namanworth S. 
(1998). Dose-related ethanol-like effects of the NMDA antagonist, ketamine, in 
recently detoxified alcoholics. Archives of General Psychiatry, 55, 354–60. 
 
Lahti, A. C., Warfel, D., Michaelidis, T., Weiler, M. A., Frey, K., & Tamminga, C. 
A. (2001). Long-term outcome of patients who receive ketamine during 
research. Biological Psychiatry, 49, 869-875. 
 
Lanning, C.F., Harmel, M.H., 1975. Ketamine anaesthesia. Annual Review of 
Medicine. 26, 137–141. 
 
	 119	
McGirr, A., Berlim, M. T., Bond, D. J., Fleck, M. P., Yatham, L. N., & Lam, R. W. 
(2015). A systematic review and meta-analysis of randomized, double-blind, 
placebo-controlled trials of ketamine in the rapid treatment of major depressive 
episodes. Psychological Medicine, 45, 693-704. 
 
Mion, G., & Villevieille, T. (2013). Ketamine pharmacology: an update 
(pharmacodynamics and molecular aspects, recent findings). CNS Neuroscience & 
Therapeutics, 19, 370-380. 
 
Moore, K. (2004). A commitment to clubbing. Peace Review, 16(4), 459-465. 
 
Morgan, C. J., Mofeez, A., Brandner, B., Bromley, L., & Curran, H. V. (2004). 
Ketamine impairs response inhibition and is positively reinforcing in healthy 
volunteers: a dose–response study. Psychopharmacology, 172, 298-308. 
 
Morley, S., Williams, A. C., & Black, S. (2002). A confirmatory factor analysis of 
the Beck Depression Inventory in chronic pain. Pain, 99, 289–298.  
 
Murrough, J. W., Iosifescu, D. V., Chang, L. C., Al Jurdi, R. K., Green, C. E., Perez, 
A. M., ... & Charney, D. S. (2013). Antidepressant efficacy of ketamine in treatment-
resistant major depression: a two-site randomized controlled trial. American Journal 
of Psychiatry, 170, 1134-1142. 
 
	 120	
Murrough, J. W., Perez, A. M., Pillemer, S., Stern, J., Parides, M. K., aan het Rot, 
M., ... & Iosifescu, D. V. (2013). Rapid and longer-term antidepressant effects of 
repeated ketamine infusions in treatment-resistant major depression. Biological 
Psychiatry, 74, 250-256. 
 
Newport, D. J., Carpenter, L. L., McDonald, W. M., Potash, J. B., Tohen, M., 
Nemeroff, C. B., & APA Council of Research Task Force on Novel Biomarkers and 
Treatments. (2015). Ketamine and other NMDA antagonists: early clinical trials and 
possible mechanisms in depression. American Journal of Psychiatry, 172, 950-966. 
 
Niesters, M., Martini, C., & Dahan, A. (2014). Ketamine for chronic pain: risks and 
benefits. British journal of clinical pharmacology, 77(2), 357-367. 
 
Niesters, M., Martini, C., & Dahan, A. (2014). Ketamine for chronic pain: risks and 
benefits. British Journal of Clinical Pharmacology, 77, 357-367. 
 
Nourozi, A., Talebi, H., Fateh, S., Mohammadzadeh, A., Eghtesadi-Araghi, P., 
Ahmadi, Z., ... & Mohebbi, A. (2010). Effect of adding ketamine to pethidine on 
postoperative pain in patients undergoing major abdominal operations: a double 
blind randomized controlled trial. Pakistan journal of biological sciences, 13, 1214-
1218. 
 
Pincus, T., & Williams, A. (1999). Models and measurements of depression in 
chronic pain. Journal of Psychosomatic Research, 47, 211–219.  
 
	 121	
Reich, D. L., & Silvay, G. (1989). Ketamine: an update on the first twenty-five years 
of clinical experience. Canadian Journal of Anaesthesia, 36, 186-197. 
 
Romeo, B., Choucha, W., Fossati, P., & Rotge, J. Y. (2015). Meta-analysis of short-
and mid-term efficacy of ketamine in unipolar and bipolar depression. Psychiatry 
Research, 230, 682-688. 
 
Schwartzman, R. J., Grothusen, J., Kiefer, T. R., & Rohr, P. (2001). Neuropathic 
central pain: epidemiology, etiology, and treatment options. Archives of 
Neurology, 58, 1547-1550. 
 
Shelton, K. L. (2004). Substitution profiles of N-methyl-D-aspartate antagonists in 
ethanol-discriminating inbred mice. Alcohol, 34, 165-175. 
 
Sigtermans, M. J., van Hilten, J. J., Bauer, M. C., Arbous, M. S., Marinus, J., Sarton, 
E. Y., & Dahan, A. (2009). Ketamine produces effective and long-term pain relief in 
patients with Complex Regional Pain Syndrome Type 1. Pain,145, 304-311. 
 
Tracey, I., & Mantyh, P. (2007). The cerebral signature for pain perception and its 
modulation. Neuron, 55, 377–391. 
 
Treede, R. D., Jensen, T. S., Campbell, J. N., Cruccu, G., Dostrovsky, J. O., Griffin, 
J. W., ... & Serra, J. (2008). Neuropathic pain redefinition and a grading system for 
clinical and research purposes. Neurology, 70, 1630-1635. 
 
	 122	
Turk, D. C., & Salovey, P. (1984). Chronic pain as a variant of depressive disease: A 
critical reappraisal. Journal of Nervous and Mental Disease, 172, 398–404. 
 
Valentine, G. W., Mason, G. F., Gomez, R., Fasula, M., Watzl, J., Pittman, B., ... & 
Sanacora, G. (2011). The antidepressant effect of ketamine is not associated with 
changes in occipital amino acid neurotransmitter content as measured by [1H]-
MRS. Psychiatry Research: Neuroimaging, 191, 122-127. 
 
White, P. F. (1982). Ketamine-its pharmacology and therapeutic 
uses. Anesthesiology, 56, 119-136. 
 
Zarate, C. A., Singh, J. B., Carlson, P. J., Brutsche, N. E., Ameli, R., Luckenbaugh, 
D. A., ... & Manji, H. K. (2006). A randomized trial of an N-methyl-D-aspartate 
antagonist in treatment-resistant major depression. Archives of general 
psychiatry, 63, 856-864. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	 123	
Part 3: Critical Appraisal 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	 124	
Overview 
The following critique will provide the reader with a reflection on the process 
of completing my DClinPsy research project. Conducting the major research project 
has been a challenging but ultimately rewarding experience. Over the course of the 
project, I have grown as a researcher, enhanced my critical thinking skills, and have 
found my clinical practice has significantly benefited from engaging in this process. 
Thus, highlighting the unique benefits and qualities that clinical training offers to 
those who are fortunate enough to embark on the journey. In the following review, I 
hope to allow the reader to gain a sense of my experiences and reflections alongside 
what I have gained from the experience. I will start by discussing the process of 
choosing a research topic. I then will provide reflections on the broader aspects of 
conducting the research. I then conclude with some reflections on working with 
individuals who live with chronic pain. 
 
Choosing a Research Topic 
Upon embarking on my training, I can remember speaking with a fellow 
trainee, soon after starting the course, and them telling me what research project they 
hoped to carry out and whom they were planning to contact to supervise it. I 
remember being surprised that someone had seemingly already planned out their 
research path but also excited to keep my options open and begin to build an image 
of what I would be interested in researching.  
During my first year placement, I worked with several people who had been 
managing chronic pain for a significant number of years. I researched this area and 
became interested in the psychological therapies which are used to help those living 
with pain. I was particularly interested in the interaction between pain and mood 
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disorders and how closely the two were linked. I was intrigued by the wide variety of 
theories that attempt to explain the co-occurrence of pain and depression and the 
need to integrate psychological ways of conceptualising the two concepts with 
evidence from the field of neuroscience. Further, evidence showing how the presence 
of depressed mood was associated with poorer outcomes in pain management 
highlighted the importance of providing appropriate care to this population. 
During the DclinPsy psychopharmacology teaching, I began to develop an 
interest in recreational substances and the fertile grounds for research that seemed to 
be developing around this topic. I became interested in the work of UCL's Clinical 
Psychopharmacology unit (CPU) and in particular the recent research which had 
been occurring with regards to the drug ketamine. The rapid-acting anti-depressant 
qualities that were being demonstrated in research intrigued me, as did the research 
looking into the use of MDMA and ketamine in the treatment of post-traumatic stress 
disorder. In response to this, I began to develop an interest in the use of these 
medications alongside psychotherapy to improve outcomes. 
Thus, when it came to the time that we would start thinking about research 
projects the combination of investigating the drug ketamine within a chronic pain 
population appealed to me. I was interested in the previous literature which has 
indicated ketamine’s ability to produce analgesia in patients experiencing chronic 
neuropathic pain, and the possible mechanisms that may underlie this. Furthermore, I 
had not had an opportunity to work in an adult health setting during my training. 
Thus, I felt that I would gain invaluable clinical and research experience through the 
opportunity to work within this setting. 
During the development phase of the research, I had the opportunity to work 
with researchers from the CPU, a consultant anaesthesiologist from the study site and 
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a fellow trainee. This proved to be an interesting and invaluable experience. Initially, 
the range of perspectives allowed broad discussions about the research topic and 
possible areas of interest. By drawing on the expertise of my supervisors this then 
was able to become more focused and take shape as a research project. This period of 
formulating the research question and developing what we would explore was a 
period of the project that I particularly enjoyed. This gave me a sense of what it was 
like to be part of a research team conducting work in clinical settings. 
 
NHS Ethics and the JRO 
One area of particular difficulty that our project encountered was navigating 
the NHS ethics and UCL Joint Research Office (JRO) procedures. Indeed, this was a 
substantial piece of work which was further complicated by inconsistent responses 
from the JRO in the initial stages of our study. Unfortunately, our JRO caseworker 
was changed several times, and it was difficult getting a response from the JRO with 
regards to work that we had handed in for approval. We were told that our 
caseworker had left their role, or that our new caseworker was on leave. At times this 
was particularly frustrating. However, we found that the best method of managing 
our difficulties was to systematically contact the various workers we had been in 
contact with at the JRO to ensure that our project was being assessed. Unfortunately, 
as a result of these setbacks, it meant that we were unable to gain ethical approval 
until December 2017. On reflection, this provided me with a valuable experience into 
how important the administration in the early stages of a study is to the success of the 
research as a whole. In particular, the knock-on effect that difficulties of this nature 
can have on a research project. For our project, this meant a much shorter time frame 
for piloting the study and collecting data.  
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Recruitment and Sample 
During the initial planning phase of the project, we put much thought into the 
recruitment process. This involved meeting with consultant anaesthetists, nurses and 
other members of staff at the study site. We anticipated that recruiting almost 80 
participants into the study may be a challenge. However, it was deemed that this 
would be possible as we would be testing participants during their routine treatment.   
Several issues were identified early on in the recruitment process. Firstly, 
there were not as many ketamine patients being booked into to receive this treatment 
as had initially been estimated. Thus, there were far fewer ketamine patients being 
treated on a weekly basis than lidocaine patients. In addition to this, many of the 
ketamine patients that were contacted did not meet the inclusion criteria. As the 
study moved forward, the task of getting enough participants became quite daunting. 
A further complication with regards to recruitment was the high drop out rate 
that we experienced in our study. Although participants were often enthusiastic about 
the study in the preliminary phone call, on testing days many potential participants 
dropped out due to being to too much pain. Indeed, frequently on testing days we 
could have up to six people booked in for testing but due to drop-outs only test one 
person. Although wholly understandable, as a researcher this could be quite 
disheartening particularly as we approached the end of our agreed testing period.   
However, when I reflect on my interactions with those who participated in 
this study, I am most struck by the openness, curiosity and wiliness to be a part of the 
project. The majority of participants I met showed a genuine curiosity in the 
research. There was also a wish to contribute and be part of the process of adding to 
the evidence base for treatments that, from conversations with many participants, 
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appeared to have had a real positive impact on their life. Indeed, I heard many 
anecdotes from participants about their journey to receiving treatment at the study 
site. Many participants reflected how grateful they were to be under the care of the 
study site. A common theme that emerged from discussions with participants was 
how the study site represented a ‘last chance’ to find a treatment that would help 
manage their pain.  
 
Working at the Study Site and Coordinating with the Clinical Team   
Conducting the study in a working NHS service provided a valuable 
opportunity to experience how researchers can carry out work while being embedded 
in a clinical environment. One of the highest priorities for myself as a researcher was 
to try and have as little of an impact on the study sites day-to-day functioning as 
possible. Thus, being prepared with a clear schedule for each testing day was 
essential. Particularly, communicating this clearly with the clinical team to manage 
the testing schedule in conjunction with the team’s priorities for treating patients. 
Furthermore, we found that it was particularly important to coordinate with the 
nursing team and nursing assistants. Building strong working relationships with these 
team members was undoubtedly instrumental to the success of our work at the study 
site. Indeed, it was essential for us as a research team to let the staff group know 
about our appreciation, and this was most often shown with edible gifts. 
Throughout the study, it was a pleasure to work with the team at the study 
site. I was grateful for the unequivocal support that the project received from all the 
staff members I came into contact with. Furthermore, the staff team showed a 
genuine interest in our study, the scientific justification for what we were doing, and 
a wider interest in our training and backgrounds as trainees. Many useful discussions 
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were had with staff members which allowed me to gain a deeper understanding of 
the work that the team was carrying out. However, in the planning phases of the 
research, these discussions allowed us to make critical adjustments to the design of 
our study so that the research had as little impact on the day-to-day functioning of 
the study site as possible. 
 
Analysis  
Moving from the testing phase to analysing and writing-up the data was an 
interesting shift. I had enjoyed the day-to-day of interacting with participants and 
staff members during the study. Once data collection had finished there was a very 
abrupt change in priorities. The beginning of the analysis involved focusing on 
minute statistical details. Many of the variables that we had planned to enter into our 
analysis were not normally distributed. Thus, I had to spend a significant amount of 
time applying transformations and exploratory analysis to the data. An added 
complication was that we had planned to conduct a mixed between-within subject's 
ANOVA, a statistical analysis that has no non-parametric equivalent. Thus, careful 
consultation of statistical manuals, internet forums and supervisors was utilized to 
make an informed decision on the best course of action. It was decided, based on the 
work of Field (2013), that carrying out the ANOVAs was still the most robust means 
of testing our data. This was based on several factors. Firstly, in samples of 40 or 
more with no outliers the sampling distribution is usually normal. Secondly, where 
possible it is preferable to carry out a robust analysis such as an F-test. Thirdly, there 
is no non-parametric equivalent of a mixed ANOVA. I found this a particularly 
challenging period of the project as there was always a feeling that more could be 
done, more could be read or understood to provide the best outcome for the project. 
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Limitations when Assessing Mood in the Chronic Pain Population 
One of the greatest challenges in designing the study was deciding how we 
would measure mood in the chronic pain population. In particular, the tension 
between using measures which had been used in the previous researching looking 
into the antidepressant or reinforcing properties of ketamine and those that are used 
to measure mood in a chronic pain population. The Beck Depression Inventory 
(BDI) has been utilized in many studies investigating the antidepressant and 
reinforcing properties of ketamine. Thus, when considering comparability to these 
studies, it presents as a favourable measure.  However, many depression measures, 
such as the BDI, include items which measure the prevalence of somatic and 
vegetative symptoms, such as sleep difficulties and health worries. Thus, these 
measures have been found to lack validity in a chronic pain population. Thus, we 
decided to utilize the Hospital Anxiety and Depression Scale (HADS) as it was the 
only scale that had been developed to be used in the context of medical problems. 
Thus, omitted somatic and vegetative items from the measure. In addition to this, we 
decided to employ the PHQ-2 and simple NRS that asked participants how depressed 
they were feeling at that moment in time. The decision to include these measures was 
two-fold. Firstly, because they had been used in the previous literature investigating 
the effects of ketamine on mood and reinforcing effects. Secondly, neither of these 
measures included any somatic items. In hindsight the use of these measures was 
problematic. In particular, the lack of specificity and broad questions employed by 
the measures. This was shown in the results of this study where both the PHQ-2 and 
Depression NRS scores were significantly reduced from baseline to one-week 
follow-up. However, this was not replicated with the HADS data.  
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Participants Reported Experiences of Chronic Pain 
Living with chronic pain can be an all-encompassing experience which has 
significant and possibly debilitating consequences on people's lives. Treatment is 
often complicated by there being an unclear cause for the pain, high frequencies of 
poor response to treatment and psychological factors which also need to be taken 
into account. Indeed, patients route to diagnoses can be challenging with the lack of 
physiological evidence often leading to a misattribution of psychological factors, and 
feelings of hopelessness as patients are not responding to treatment. Further to this, 
patients can also undergo significant investigations and invasive treatments which 
further exacerbate their pain.   
Over the course of the research project, I was struck by the stories that 
patients told me about their journey to being diagnosed. Many patients spoke of the 
hopelessness they felt before receiving a diagnosis, and the many professionals that 
they consulted before receiving treatment at the study site. In addition to this, there 
was often a strong sense of loss that patients had with regards to their personal life, 
professional life and their sense of who they were.  
I can remember being struck by how prominent the feeling of difference was 
in participant’s sense of self. Stories were often segmented into how patient’s lives 
were before pain and then their current life. Or indeed, their past selves and present 
selves. I can remember one patient speaking of her previous career as a successful 
musician, she spoke of leading a full life characterized by exercise, travel and 
performance. However, since living with chronic pain she felt that the parts of 
herself, which used to enjoy these aspects of her life, had disappeared. She told me 
that she had retreated from her social network as she felt ashamed that she was no 
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longer able to be her former self. This led to her loosing touch with many close 
friends.   
I was also struck by the emotional impact that listening to participant's stories 
had on me. Some participants were experiencing significant amounts of emotional 
distress, and many participants had also endured a range of challenging life events 
which were related to their pain. I was often left feeling hopeless about their 
difficulties as though I could do nothing to help them or their situation. Indeed, this 
was likely a communication of how the participants felt themselves. However, it also 
made me reflect on the position of the supporting family members and the lack of 
agency that may sometimes be felt when unable to help a loved one. I was able to 
reflect on this experience with my fellow research colleagues and team members at 
the study site. 
During this research project, I was unfortunate enough to be in a significant 
accident which left me with injuries that will likely cause me some pain for years to 
come. Thus, I had the experience of contemplating how my life may involve 
managing some degree of pain whilst working with participants who were already 
managing life with chronic pain. This allowed me to reflect on how much one can 
take health and wellness for granted but also how quickly things can change for 
individuals.  
 
Conclusion 
In conclusion, the research project has provided a challenging and fulfilling 
experience from which I have learned a great deal. Although there were a number of 
limitations of the empirical paper which could be improved there were also strengths 
in the studies design and execution. The experience I gained working with both the 
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staff team and patients at the study site highlighted how crucial the ongoing work at 
the study site is. Meeting participants highlighted how complex one’s experience of 
chronic pain is. In particular, how chronic pain can affect relationships, sense of self 
and well being. I was struck by the kind and sensitive nature of all the members of 
staff working with this patient group. In particular, the intuitive and open way of 
meeting patients needs. However, I was also left with a sense of the emotional 
demand that working within this patient group may have on the clinician.  
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This thesis forms part of a joint research project with fellow DClinPsy trainee 
Catherine Trotman (Trotman, 2018). 
Recruitment and testing were undertaken jointly by Catherine and myself. 
We each tested approximately half of the participants. Post-doc Dr Will Lawn 
conducted two testing sessions when myself and Catherine were unable to conduct 
testing. 
Catherine investigated the effect of sub-anaesthetic doses of ketamine on 
cognitive functioning and so her paper includes an analysis of data from several tests 
of cognitive functioning (Serial Sevens, Story Recall Sub-Test of Rivermead 
Behavioural Memory Test and a task of Verbal Fluency). These tasks were 
completed by all participants but are not discussed within the current project. 
The current project focused on on the effect of sub-anaesthetic doses of 
ketamine on pain, mood and subjective drug effects. Data was collected at three time 
points during patient treatment (baseline, mid-infusion and post-infusion). The 
current paper also collected data during a one-week follow-up phone call. This was 
not part of the protocol for Catherine Trotman’s project. 
Data was scored and entered into a database by myself and Catherine 
Trotman. Both empirical papers include the analysis of sample demographics and 
pain numerical rating scales. The current paper includes the analysis of one-week 
follow up data, as well as scores on measures of anxiety, depression, and subjective 
drug effects. 
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Appendix 2: NHS Ethics Approval from South Central 
Berkshire NHS Research Ethics Committee 
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Appendix 3. Consent Form 
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Appendix 4. Participant Information Sheet 
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Appendix 5. Hospital Anxiety and Depression Scale 
(HADS)and Patient Health Questionnaire-2 (PHQ-2) 
 
Removed Due to Copyright 
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Appendix 6. Pain Numerical Rating Scales 
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HOW ARE YOU FEELING? 
 
Instructions:   On each scale, please circle the number that best 
describes how you feel RIGHT NOW. 
 
Pain intensity 
No pain            Extremely 
 0 1 2 3 4 5 6 7 8 9 10 intense pain 
 
 
Pain distress 
Not            Extremely 
distressing 0 1 2 3 4 5 6 7 8 9 10 distressing 
 
 
Pain interference 
Does not            Interferes with 
interfere 0 1 2 3 4 5 6 7 8 9 10 everything 
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Appendix 7. Subjective Drug Effects Numerical Rating 
Scales 
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Appendix 8. The Alcohol Use Disorders Identification Test 
(AUDIT) and the Highest Level of Educational Attainment 
 
 
 
Removed Due to Copyright 
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Appendix 9. Secondary Analysis, Mann-Whitney U Test 
Results 
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1. Pain 
 
Acute Effects  
 Pain Intensity  
Exploratory analysis of the pain intensity change score data was conducted using 
Mann–Whitney U tests. Results showed that the ketamine group had a significantly 
larger reduction in pain intensity from the lidocaine group from baseline to mid-
infusion U=178.000, z=-3.56, p<0.001, r=0.47. This difference was also significant 
when comparing the change scores from baseline to post-infusion U=215.000, z=-
2.3516, p=0.019, r=0.32.  
 
Baseline and one-week follow-up 
 Pain Intensity 
Exploratory non-parametric analysis, using Mann–Whitney U tests, of the base line 
and one-week-follow-up pain intensity change score data showed no significant 
differences between the ketamine group and the lidocaine U=402.000, z=0.515, 
p=0.607, r=0.07. 
 
Pain Interference 
Exploratory analysis, using Mann–Whitney U tests, of the baseline and one-week-
follow-up pain interference change score data showed no significant differences 
between the ketamine group and the lidocaine U=413.000, z=0.929, p=0.353, 
r=0.01. 
 
2. Drug Effects 
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Dizziness 
Exploratory Mann-Whitney U analysis of change scores showed that the lidocaine 
treatment group showed a significantly higher increase in subjective feelings of 
dizziness, than the ketamine group, when comparing baseline and mid-infusion 
scores U=578.000, z=3.364, p<0.001, r=0.45 
 
Drowsiness 
Exploratory Mann-Whitney U tests showed that the ketamine group almost met 
significance for having greater reduction in drowsiness when comparing baseline 
scores and post-infusion scores U=240.000, z=-1.902, p=0.057. 
 
Depression NRS 
Acute: Exploratory analysis, using Mann–Whitney U tests of change score data 
showed that the ketamine group had a significantly larger reduction in self reported 
depression than the lidocaine group from baseline to mid infusion U=249.500, z=-
2.19, p=0.029, r=0.29. No other change scores were significant. 
 
Baseline and one-week follow-up: No significant differences were found between the 
ketamine and lidocaine groups when comparing pre-infusion data and the data 
collected at the one-week follow-up when using Mann-Whitney U tests. 
 
Nausea 
Exploratory Mann-Whitney U tests revealed that participants in the ketamine group 
were found to have a significantly greater reduction in feelings of nausea when 
	 160	
comparing baseline and post-infusion scores U=217.500, z=-2.482, p=0.013, r=-
0.34.  
 
Visual Distortion 
Exploratory Mann-Whitney U tests revealed that the ketamine group showed a 
significantly greater reduction in visual distortions when comparing the baseline and 
post infusion scores U=252.500, z=-1.9629, p=0.050, r=-0.26.  
 
Feeling a Drug effect 
Exploratory Mann-Whitney U tests revealed that the ketamine group showed a 
significantly greater reduction in feeling a drug effect, than the lidocaine group, 
when comparing results from the mid-infusion and post-infusion time points 
U=168.000, z=-2.898, p=0.004, r=-0.40.   
 
Feeling High 
Exploratory Mann-Whitney U tests revealed that ketamine patients also showed a 
significantly greater reduction in self-reported feelings of being high on the 
treatment, when comparing mid-infusion and post-infusion data U=149.000, z=-
3.534, p<0.001, r=-0.49.  
 
 
 
 
 
